QT INTERVAL IN CARDIOLOGIC CLINICS
Анотація
QT interval, reflecting depolarization and repolarization processes, and finally, ventricles ejection function has key value in cardiac activity. As response for structure and function abnormalities of cardiomyocytes ion channels, pathological states, drug effects, QT may change both prolongation and shortening. In review presented collected data on QT and its’ dispersion changes in main pathological states and effects of various drug groups.
Завантаження
##plugins.generic.usageStats.noStats##
Посилання
1. Wever E. Sudden death in patients without structural heart disease / E. Wever, d. Robles // J Am Coll Cardiol. – 2004. – № 43. – C. 1137-1144.
2. Priori S. Task force on sudden cardiacdeath of the European society of cardiology / S. Priori, E. Aliot, C. Blomstrom-Lundqvist // EurHeart J. – 2001. – № 22. – C. 1374-1450.
3. Philippe M. Short QT syndrome. Update on a recent entity / M. Philippe, F. Extramiana, P. Sbragia // Archives of Cardiovascular Disease. – 2008. – № 101. – C. 779-786.
4. QT interval as a cardiac risk factor in a middleaged population / J. Karjalainen, A. Reunanen, P. Ristola, M. Viitasalo [et al.] // Heart. – 1997. – C. 543-548.
5. QT interval variables from 24 hour electrocardiography and the two-year risk of sudden death / A. Algra, J. Tijssen, J. Roelandt, J. Pool, J. Lubsen [et al.] // Br Heart J. – 1993. – C. 43-48.
6. Idiopathic short QT interval: a new clinical syndrome? / I. Gussak, P. Brugada, J. Brugada, R. Wright, S. Kopecky, B. Chaitman [et al.] // Cardiology. – 2000. – C. 99-9102.
7. Gaita F. Short QT syndrome. A familial cause of sudden death / F. Gaita, C. Giustetto, F. Bianchi // Circulation. – 2003. – № 108. – C. 965-970.
8. Wojciech Z. Long QT Syndrome and Short QT Syndrome / Z. Wojciech // Progress in Cardiovascular Diseases. – 2008. – № 3. – C. 264-278.
9. Priori S. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene / S. Priori, S. Pandit, I. Rivolta // Circ Res. – 2005. – № 96. – C. 800-807.
10. Bellocq C. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome / C. Bellocq, V. Ginneken, C. Bezzina // Circulation. – 2004. – № 109. – C. 2394-2397.
11. Short QT interval syndrome: a case report / A. Kirilmae, R. Uluso, E. Kardesoglu, N. Ozmen, E. Demilrap [et al.] // J Electrocardiol. – 2005. – C. 371-374.
12. Short QT Syndrome. Should we push the frontier forward? / P. Maury, L. Hollington, A. Duparc, R. Brugada [et al.] // Heart Rhythm. – 2005. – C. 1135-1137.
13. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2 / K. Hong, P. Bjerregaard, I. Gussak, R. Brugada [et al.] // J Cardiovasc Electrophysiol. – 2005. – C. 394-396.
14. Hong K. De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero / K. Hong, D. Piper, A. Diaz-Valdecantos // Cardiovasc Res. – 2005. – № 68. – C. 433-440.
15. Short QT syndrome: a case report and review of the literature / L. LX, W. Zhou, X. Zhang, Q. Cao, K. Yu, C. Zhu [et al.] // Resuscitation. – 2006. – C. 115-121.
16. Hiroto I. "Gender difference in QTc prolongation of people with mental disorders" / I. Hiroto, K. Toshiaki, I. Shigenobu // Annals of General Hospital Psychiatry. – 2004. – № 3. – C. 2832-2833.
17. Effects of Aging and Gender on QT Dispersion in an Overtly Healthy Population / J. Kassotis, C. Constantinos, K. Ashwani, T. Aneesh, J. Reiffel [et al.] // Pacing and Clinical Electrophysiology Volume. – 32. – C. 1121-1126.
18. Moss A. Long QT syndrome / A. Moss, J. Robinson // Heart Dis Stroke. – 1992. – № 1. – C. 309-314.
19. Goldenberg I. Moss, Wojciech Zareba / I. Goldenberg, J. Arthur // QT Interval: How to Measure It and What Is "Normal" Journal of Cardiovascular Electrophysiology. – 2006. – № 17. – C. 333-336.
20. Bazett H. An analysis of the time-relations of electrocardiograms" / H. Bazett // Heart. – 1920. – № 7. – C. 353-370.
21. Fridericia L. "The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease" / L. Fridericia // Acta Medica Scandinavica. – 1920. – № 53. – C. 469-486.
22. "An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)" / A. Sagie, M. Larson, R. Goldberg, J. Bengston, D. Levy [et al.] // Am J Cardiol. – 1992. – C. 797-801.
23. Donger C. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome / C. Donger, I. Denjoy, M. Berthet // Circulation. – 1997. – № 96. – C. 2778-2781.
24. Paulussen A. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 / A. Paulussen, R. Gilissen, M. Armstrong // J Electrocardiol. – 2007. – № 57. – C. 251-258.
25. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome / M. Curran, I. Splawski, K. Timothy, G. Vincent, E. Green, M. Keating [et al.] // Cell. – 1995. – C. 795-803.
26. Wang Q. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome / Q. Wang, J. Shen, I. Splawski // Cell. – 1995. – № 80. – C. 805-811.
27. Splawski I. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 / I. Splawski, J. Shen, K. Timothy // Circulation. – 2000. – № 102. – C. 1178-1185.
28. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long Qt syndrome genetic testing / 7. Tester, M. Will, C. Haglund, M. Ackerman [et al.] // Heart Rhythm. – 2005. – C. 507-517.
29. Mutations in the hminK gene cause long QT syndrome and suppress IKs function / I. Splawski, M. Tristani-Friouzi, M. Lehman, M. Sanguinetti, M. Keating [et al.] // Nat Genet. – 1997. – C. 338-340.
30. Abbott G. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia / G. Abbott, F. Sesti, I. Splawski // Cell. – 1999. – № 97. – C. 175-187.
31. Hiroshi M. The QT syndromes: long and short / M. Hiroshi, W. Jiashin, P. Douglas // Lancet. – 2008. – № 372. – C. 750-763.
32. Plaster N. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome / N. Plaster, R. Tawil, M. Tristani-Firouzi // Cell. – 2001. – № 105. – C. 511-519.
33. Splawski I. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism / I. Splawski, K. Timothy, L. Sharpe // Cell. – 2004. – № 119. – C. 19-31.
34. Vatta M. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome / M. Vatta, M. Ackerman, B. Ye // Circulation. – 2006. – № 114. – C. 2104-2112.
35. Short QT syndrome and atria fibrillation caused by mutation in KCNH2 / K. Hong, P. Bjerregaard, I. Gussak, R. Brugada [et al.] // J Cardiovasc Electrophysiol. – 2005. – C. 394-396.
36. Hong K. De novo KCNQ1 mutation responsible for atrial fi lbrillation and short QT syndrome in utero / K. Hong, D. Piper, A. Diaz-Valdecantos // Cardiovasc Res. – 2005. – № 68. – C. 433-440.
37. Brugada R. Sudden death associated with short-QT syndrome linked to mutations in HERG / R. Brugada, K. Hong, R. Dumaine // Circulation. – 2004. – № 109. – C. 30-35.
38. Antzelevitch C. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death / C. Antzelevitch, G. Pollevick, J. Cordeiro // Circulation. – 2007. – № 115. – C. 442-449.
39. Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillation / S. Das, S. Makino, Y. Melman, M. Shea, S. Goyal, A. Rosenzweig, C. Macrae, P. Ellinor [et al.] // Heart Rhythm. – 2009. – C. 1146-1153.
40. N Engl J Med / S. Hohnloser, H. Crijns, v. Eickels, C. Gaudin, R. Page, C. Torp-Pedersen, S. Connolly [et al.] // . – 2009. – C. 668-678.
41. Novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation / T. Makiyama, M. Akao, S. Shizuta, T. Doi, K. Nishiyama, Y. Oka, S. Ohno, Y. Nishio, K. Tsuji, H. Itoh, T. Kimura, T. Kita, M. Horie [et al.] // J Am Coll Cardiol. – 2008. – C. 1326-1334.
42. mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation / B. Benito, R. Brugada, R. Perich, E. Lizotte, J. Cinca, L. Mont, A. Berruezo, J. Tolosana, X. Freixa, P. Brugada, J. Brugada [et al.] // Heart Rhythm. – 2008. – C. 1434-1440.
43. KCNQ1 mutation Q147R is associated with atrial fibrillation and prolonged QT interval / A. Lundby, L. Ravn, J. Svendsen, S. Olesen, N. Schmitt [et al.] // Heart Rhythm. – 2007. – C. 1532-1541.
44. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2 / K. Hong, P. Bjerregaard, I. Gussak, R. Brugada [et al.] // J Cardiovasc Electrophysiol. – 2005. – C. 394-396.
45. Short QT Syndrome: a familial cause of sudden death / F. Gaita, C. Giustetto, F. Bianchi, C. Wolpert, R. Schimpf, R. Riccardi, S. Grossi, E. Richiardi, M. Borggrefe [et al.] // Circulation. – 2003. – C. 965-970.
46. Friedman P. Sotalol and a Broken Heart / P. Friedman, S. Montgomery, N. Matas // J Cardiovasc Electrophysiol. – 2009. – № 28. – C. 149-154.
47. Quinidine for pharmacological cardioversion of atrial fibrillation: a retrospective analysis in 501 consecutive patients / B. Schwaab, A. Katalinic, U. Boge, J. Loh, P. Blank, T. Kolzow, D. Poppe, H. Bonnemeier [et al.] // Ann Noninvasive Electrocardiol. – 2009. – C. 128-136.
48. Nibentan in arresting acute atrial fibrillation: risk or benefit? / A. Chapurnykh, O. Solov'ev, A. Zavalin, E. Pavlov, D. Efremov [et al.] // Ter Arkh. – 2008. – C. 41-45.
49. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome / D. Darbar, J. Kimbrough, A. Jawaid, R. McCray, M. Ritchie, D. Roden [et al.] // J Am Coll Cardiol. – 2008. – C. 836-842.
50. Long QT syndrome induced by cordaron and quinidine / E. Mironchik, T. Dolgoshei, T. Liskovich, G. Madeshkina, A. Kokhkovski, A. Tyshchenko [et al.] // Klin Med (Mosk). – 2007. – C. 69-71.
51. Nagra B. Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale / B. Nagra, G. Ledley, B. Kantharia // J Cardiovasc Pharmacol Ther. – 2005. – № 10. – C. 191-195.
52. Singh S. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study / S. Singh // Card Electrophysiol Rev. – 2003. – № 7. – C. 225-228.
53. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome / A. Ricardo, P. Riera, A. Hiroshi, C. Ferreira, C. Ferreira, E. Schapachnik, S. Dubner, L. Zhang [et al.] // Cardiol J. – 2008. – C. 209-219. Shantsila E. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias / E. Shantsila, W. Timothy, Y. Gregory // Europace. – 2007. – № 9. – C. 37-44.
54. Gupta A. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes / A. Gupta, A. Lawrence, K. Krishnan // Am Heart J. – 2007. – № 153. – C. 891-899.
55. Thomas D. Modulation of HERG potassium channel function by drug action / D. Thomas, C. Karle, J. Kiehn // Ann Med. – 2004. – № 36. – C. 41-46.
56. Selzer A. Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias / A. Selzer, H. Wray // Circulation. – 1964. – № 30. – C. 17-26.
57. Wolbrette D. Risk of proarrhythmia with class III antiarrhythmic agents: Sex-based differences and other issues / D. Wolbrette // Am J Cardiol. – 2003. – № 91. – C. 39-44.
58. Singh B. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs / B. Singh, N. Wadhani // J Cardiovasc Pharmacol Ther. – 2004. – № 9. – C. 85-97.
59. Antonaccio M. Encainide / M. Antonaccio, A. Gomoll, J. Byrne // Cardiovasc Drugs Ther. – 1989. – №3. – C. 691-710.
60. Antonaccio M. Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol / M. Antonaccio, A. Gomoll // Am J Cardiol. – 1993. – № 72. – C. 27-37.
61. Fitton A. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias / A. Fitton, E. Sorkin // Drugs. – 1993. – № 46. – C. 678-719.
62. Singh B. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent / B. Singh // Am J Cardiol. – 1996. – № 78. – C. 41-53.
63. Torsades de pointes ventricular tachycardia induced by intravenous amiodarone / A. Makai, L. Rudas, G. Liszkai, T. Fazekas [et al.] // Orv Hetil. – 2003. – C. 241-247.
64. Roukoz H. Dofetilide: a new class III antiarrhythmic agent / H. Roukoz, W. Saliba // Expert Rev Cardiovasc Ther. – 2007. – № 5. – C. 9-19.
65. Saliba W. Dofetilide (Tikosyn): a new drug to control atrial fibrillation / W. Saliba // Cleve Clin J Med. – 2001. – № 68. – C. 353-363.
66. Short QT Interval and Atrial Fibrillation in Patients Without Structural Heart Disease / G. Poglajen, M. Fister, B. Radovancevic, B. Vrtovec [et al.] // J Am Coll Cardiol. – 2006. – C. 1905-1907.
67. Pai G. The QT interval in atrial fibrillation / G. Pai, J. Rawles // Br Heart J. – 1989. – № 61. – C. 510-513.
68. Pai R. Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction / R. Pai, P. Varadarajan // Clin Cardiol. – 2007. – № 30. – C. 349-354.
69. Beat-to-beat QT dynamics in paroxysmal atrial fibrillation / C. Larroude, B. Jensen, E. Agner, E. Toft, C. Torp-Pedersen, K. Wachtell, J. Kanters [et al.] // Heart Rhythm. – 2006. – C. 660-664.
70. Comparison of QT dispersion during atrial fibrillation and sinus rhythm in the same patients, at normal and prolonged ventricular repolarization / B. Houltz, B. Darpo, K. Swedberg, P. Blomstrom, H. Crijns, S. Jensen, E. Svernhage, N. Edvardsson [et al.] // Europace. – 2000. – C. 20-31.
71. Soler-Soler J. QT dispersion after myocardial infarction with heart failure: additional prognostic marker? / J. Soler-Soler, E. Galve // European Heart Journal. – 1999. – № 20. – C. 1146-1148.
72. QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure / K. Spargias, S. Lindsay, G. Kawar, D. Greenwood, J. Cowan, S. Ball, A. Hall [et al.] // European Heart Journal. – 1999. – C. 1158-1165.
73. Roeinton B. The QT interval in myocardial infarction / B. Roeinton, . Khambaita, . MB // British Medical Journal. – 1953. – № 54. – C. 132-135.
74. QT Intervals in Acute Myocardial Infarction: First-Year Prognostic Implications / S. Ahnvem, C. Helmers, T. Lundmanm, D. Rehnqvistm, D. Sjogren [et al.] // Clin Cardiol. – 1980. – C. 303-308.
75. Higham P. QT dispersion and components of the QT interval in ischaemia and infarction / P. Higham, S. Furniss, R. Campbell // Br Heart J. – 1995. – № 73. – C. 32-36.
76. Use of lead adjustment formulas for QT dispersion after myocardial infarction / J. Glancy, C. Garratt, K. Woods, d. Bono [et al.] // Br Heart J. – 1995. – C. 676-679.
77. QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population / M. Manttari, L. Oikarinen, V. Manninen, M. Viitasalo [et al.] // Heart. – 1997. – C. 268-272.
78. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: results of a prospective, long-term follow-up study / M. Zabel, T. Klingenheben, M. Franz, S. Hohnloser [et al.] // Circulation. – 1998. – C. 2543-2550.
79. QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure / K. Spargias, S. Lindsay, G. Kawar, D. Greenwood, J. Cowan, S. Ball, A. Hall [et al.] // Eur Heart J. – 1999. – C. 1158-1165.
80. Predictive power of increased QT dispersion in ventricular extrasystoles and in sinus beats for risk stratification after myocardial infarction / A. Dabrowski, E. Kramarz, R. Piotrowicz, L. Kubik [et al.] // Circulation. – 2000. – C. 1693-1697.
81. Aitchison J. Time dependent variability of QT dispersion after acute myocardial infarction and its relation to ventricular fibrillation: a prospective study / J. Aitchison, R. Campbell, P. Higham // Heart. – 2000. – № 84. – C. 504-508.
82. Transient QT interval prolongation with inverted T waves indicates myocardial salvage on dual radionuclide single-photon emission computed tomography in acute anterior myocardial infarction / T. Obayashi, T. Tokunaga, T. Iiizumi, T. Shiigai, M. Hiroe, F. Marumo [et al.] // Jpn Circ J. – 2001. – C. 7-10.
83. Effects of depression on QT interval variability after myocardial infarction / R. Carney, K. Freedland, P. Stein, L. Watkins, D. Catellier, A. Jaffe, V. Yeragani [et al.] // Psychosom Med. – 2003. – C. 177-180.
84. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients / T. Clayton, J. Lubsen, S. Pocock, Z. Voko, B. Kirwan, K. Fox, P. Poole-Wilson [et al.] // BMJ. – 2005. – C. 869-869.
85. Methods of assessment and clinical relevance of QT dynamics / B. Sredniawa, A. Musialik-Lydka, P. Jarski, A. Sliwinska, Z. Kalarus [et al.] // Indian Pacing Electrophysiol J. – 2005. – C. 221-232.
86. QT interval dispersion analysis in acute myocardial infarction patients: coronary reperfusion effect / N. Lopes, C. Grupi, C. Dina, d. Gois, L. Hajjar, B. Ayub, C. Rochitte, J. Ramires, W. Hueb, R. Kalil [et al.] // Arq Bras Cardiol. – 2006. – C. 91-98.
87. Corrected QT interval prolongation: a new predictor of cardiovascular risk in patients with non-ST-elevation acute coronary syndrome / F. Gadaleta, S. Llois, V. Sinisi, J. Quiles, P. Avanzas, J. Kaski [et al.] // Rev Esp Cardiol Jun. – 2008. – C. 572-578.
88. Prominent negative T waves with QT prolongation indicate reperfusion injury and myocardial stunning / Y. Hirota, Y. Kita, R. Tsuji, H. Handa, K. Ishii, Y. Yoneda [et al.] // J Cardiol. – 1992. – C. 325-340.
89. Schwartz P. QT interval prolongation as predictor of sudden cardiac death in patients with myocardial infarction / P. Schwartz, S. Wolf // Circulation. – 1978. – № 57. – C. 1074-1077.
90. QTc interval in acute myocardial infarction: First-year prognostic implications / S. Ahnve, C. Helmers, T. Lundman, N. Rehqvist, A. Sjogren [et al.] // Clin Cardiol. – 1980. – C. 303-308.
91. Relationship between infarction location and size to QT dispersion in patients with chronic myocardial infarction / N. Hashimoto, H. Musha, A. Ozawa, Y. Imai, K. Kawasaki, O. Miyazu, J. Nagashima, T. So, F. Miyake, M. Murayama [et al.] // Jpn Heart J. – 2002. – C. 455-461.
92. Cavallini B. Dispersion of QT interval in arterial hypertension with left ventricular hypertrophy / B. Cavallini, V. Perri, M. Sali // Minerva Cardioangiol Jan-Feb. – 1996. – № 44(1-2). – C. 45-48.
93. QT-interval variability and autonomic control in hypertensive subjects with left ventricular hypertrophy / G. Piccirillo, G. Germano, R. Quaglione, M. Nocco, F. Lintas, M. Lionetti, A. Moise, M. Ragazzo, V. Marigliano, M. Cacciafesta [et al.] // Clin Sci (Lond). – 2002. – C. 363-371.
94. QT dispersion in relation to left ventricular geometry and hypertension in a population study / I. Pshenichnikov, T. Shipilova, J. Kaik, O. Volozh, J. Abina, J. Lass, D. Karai [et al.] // Scand Cardiovasc J. – 2003. – C. 87-90.
95. Left ventricular hypertrophy and QT interval in obesity and in hypertension: effects of weight loss and of normalisation of blood pressure / A. Pontiroli, P. Pizzocri, A. Saibene, A. Girola, D. Koprivec, G. Fragasso [et al.] // Int J Obes Relat Metab Disord. – 2004. – C. 1118-1123.
96. Increased myocardial repolarization lability and reduced cardiac baroreflex sensitivity in individuals with high-normal blood pressure / A. Myredal, S. Gao, P. Friberg, G. Jensen, L. Larsson, M. Johansson [et al.] // J Hypertens. – 2005. – C. 1751-1756.
97. Importance of the electrocardiographic strain pattern in patients with resistant hypertension / G. Salles, C. Cardoso, A. Nogueira, K. Bloch, E. Muxfeldt [et al.] // Hypertension. – 2006. – C. 437-442.
98. Nunes J. Cardiac structure and apnea/hypopnea index in patients with arterial hypertension and excessive weight / J. Nunes, N. Oliveira // Kidney Blood Press Res. – 2006. – № 29. – C. 159-164.
99. Relationship of electrocardiographic repolarization measures to
echocardiographic left ventricular mass in men with hypertension / K. Porthan, J. Virolainen, T. Hiltunen, M. Viitasalo, H. Vaananen, J. Dabek, T. Hannila-Handelberg, L. Toivonen, M. Nieminen, K. Kontula, L. Oikarinen [et al.] // J Hypertens. – 2007. – C. 1951-1957.
100. QT interval prolongation among patients treated with angiogenesis inhibitors / S. Ederhy, A. Cohen, G. Dufaitre, H. Izzedine, C. Massard, C. Meuleman, B. Besse, E. Berthelot, F. Boccara, J. Soria [et al.] // Target Oncol. – 2009. – C. 89-97.
101. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens / H. Elming, E. Holm, L. Jun, C. Torp-Pedersen, L. Kober, M. Kircshoff, M. Malik, J. Camm [et al.] // Eur Heart J Sep. – 1998. – C. 1391-1400.
102. Autonomic modulation and QT interval dispersion in hypertensive subjects with anxiety / G. Piccirillo, E. Viola, M. Nocco, E. Santagada, M. Durante, C. Bucca, V. Marigliano [et al.] // Hypertension. – 1999. – C. 242-246.
103. Rekiene D. JTc prolongation in hypertrophic cardiomyopathy amd arterial hypertension / D. Rekiene // Medicina (Kaunas). – 2002. – № 38. – C. 1083-1085.
104. Importance of the electrocardiographic strain pattern in patients with resistant hypertension / G. Salles, C. Cardoso, A. Nogueira, K. Bloch, E. Muxfeldt [et al.] // Hypertension Sep. – 2006. – C. 437-442.
105. Relationship between the elastic properties of aorta and QT dispersion in newly diagnosed arterial adult hypertensives / M. Gur, R. Yilmaz, R. Demirbag, A. Yildiz, S. Akyol, M. Polat, M. Bas [et al.] // Anadolu Kardiyol Derg. – 2007. – C. 275-280.
106. Arterial hypertension, left ventricular geometry and QT dispersion in a middle-aged Estonian female population / T. Shipilova, I. Pshenichnikov, J. Kaik, O. Volozh, J. Abina, M. Kalev, J. Lass, D. Karai [et al.] // Blood Press. – 2003. – C. 12-18.
107. Prolonged ventricular repolarization measured by corrected QT interval (QTc) in subclinical hyperthyroidism / M. Owecki, A. Michalak, E. Nikisch, J. Sowinski [et al.] // Horm Metab Res. – 2006. – C. 44-47.
108. Hief C. Effect of enflurane on inducibility of ventricular tachycardia / C. Hief, M. Borggrefe, X. Chen // Am J Cardiol. – 1991. – № 68. – C. 609-613.
109. Circadian rhythmicity of rate-normalized QT interval in hypothyroidism and its significance for development of class III antiarrhythmic agents / J. Sarma, K. Venkataraman, P. Nicod, R. Polikar, J. Smith, M. Schoenbaum, B. Singh [et al.] // Am J Cardiol. – 1990. – C. 959-963.
110. QT/QS2 index in patients with arterial hypertension, mitral valve prolapse and hyperthyroidism / Z. Purzycki, M. Nowicki, J. Regula, L. Bieniaszewski, K. Zaborowski, T. Zdrojewski [et al.] // Pol Tyg Lek. – 1992. – C. 576-578.
111. Hyperthyroidism is associated with lengthening of ventricular repolarization / R. Colzani, M. Emdin, F. Conforti, C. Passino, M. Scarlattini, G. Iervasi [et al.] // Clin Endocrinol (Oxf). – 2001. – C. 27-32.
112. Prolonged ventricular repolarization measured by QTc interval in hyperthyroidism / M. Owecki, A. Michalak, E. Nikisch, J. Sowinski [et al.] // Pol Merkur Lekarski. – 2005. – C. 24-27.
113. Nowak J. Influence of hyperthyroidism defined as TSH serum level on QT corrected interval dispersion (QTcd) / J. Nowak, J. Dubiel // Przegl Lek. – 2006. – № 63. – C. 123-127.
114. QTc dispersion in hyperthyroidism and its association with pulmonary hypertension / U. Guntekin, Y. Gunes, M. Tuncer, H. Simsek, H. Gumrukcuoglu, S. Arslan, A. Gunes [et al.] // Pacing Clin Electrophysiol. – 2009. – C. 494-499.
115. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women / d. Bacquer, d. Backer, M. Kornitzer, H. Blackburn [et al.] // Heart. – 1998. – C. 570-577.
116. Lehmann M. QT interval: metric for cardiac prognosis? / M. Lehmann, F. Morady // Am J Med. – 2003. – № 115. – C. 732-734.
117. Jimйnez-Candil J. QT Interval and Acute Myocardial Ischemia: Past Promises, New Evidences / J. Jimйnez-Candil, M. Cбndido // Rev Esp Cardiol. – 2008. – № 61. – C. 561-563.
118. Bijl M. Extreme QT prolongation solely due to reversible myocardial ischemia in single-vessel coronary disease / M. Bijl, F. Verheugt // Am Heart J. – 1992. – № 123. – C. 524-526.
119. Sredniawa B. Dispersion of the QT interval in unstable angina pectoris / B. Sredniawa, A. Musialik-Lydka, S. Pasyk // Pol Arch Med Wewn. – 2000. – № 103. – C. 41-45.
120. Furman N. Dynamics of QT interval dispersion in patients with ischemic heart disease during stress test as possible reflection of changes of terminal part of the T-wave / N. Furman, S. Shmatova, P. Dovgalevski // Kardiologiia. – 2007. – № 47. – C. 19-23.
121. Analysis of factors influencing QT interval dispersion in patients with stable angina / N. Furman, S. Shmatova, P. Dovgalevskii, M. Sham'iunov, V. Mukhortov [et al.] // Klin Med (Mosk). – 2009. – C. 20-23.
122. The effect of acute psychological stress on QT dispersion in patients with coronary artery disease / M. Hassan, A. Mela, Q. Li, B. Brumback, R. Fillingim, J. Conti, D. Sheps [et al.] // Pacing Clin Electrophysiol Sep. – 2009. – C. 1178-1183.
123. Higham P. QT dispersion and components of the QT interval in ischaemia and infarction / P. Higham, S. Furniss, R. Campbell // Br Heart J Jan. – 1995. – № 73. – C. 32-36.
124. Increased QT dispersion in patients with vasospastic angina / M. Suzuki, M. Nishizaki, M. Arita, T. Ashikaga, N. Yamawake, T. Kakuta, F. Numano, M. Hiraoka [et al.] // Circulation. – 1998. – C. 435-440.
125. Crow R. Prognostic significance of corrected QT and corrected JT interval for incident coronary heart disease in a general population sample stratified by presence or absence of wide QRS complex: the ARIC Study with 13 years of follow-up / R. Crow, P. Hannan, A. Folsom // Circulation. – 2003. – № 108(16). – C. 1985-1989.
126. QT interval dispersion: non-invasive marker of ischemic injury in patients with unstable angina pectoris? / O. Doven, C. Ozdol, T. Sayin, D. Oral [et al.] // Jpn Heart J Sep. – 2000. – C. 597-603.
127. Beat-to-beat QT interval variability associated with acute myocardial ischemia / T. Murabayashi, B. Fetics, D. Kass, E. Nevo, B. Gramatikov, R. Berger [et al.] // J Electrocardiol. – 2002. – C. 19-25.
128. Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary artery disease / R. Castro, G. Porphirio, S. Serra, A. Nobrega [et al.] // Braz J Med Biol Res. – 2002. – C. 685-689.
129. Effects of ischemia on repolarization in patients with single and multivessel coronary disease / D. Giedrimiene, S. Giri, A. Giedrimas, F. Kiernan, J. Kluger [et al.] // Pacing Clin Electrophysiol. – 2003. – C. 390-393.
130. Prolongation of the QTc interval is seen uniformly during early transmural ischemia / D. Kenigsberg, S. Khanal, M. Kowalski, S. Krishnan [et al.] // J Am Coll Cardiol. – 2007. – C. 1299-1305.
131. Relationship between the QTc interval at hospital admission and the severity of the underlying ischaemia in low and intermediate risk people studied for acute chest pain / J. Jimenez-Candil, M. Diego, C. Gonzalez, M. Gonzalez, F. Martin, P. Pabon, V. Ramirez, V. Leon, C. Martin-Luengo [et al.] // Int J Cardiol. – 2008. – C. 84-91.
132. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study / S. Chugh, K. Reinier, T. Singh, A. Uy-Evanado, C. Socoteanu, D. Peters, R. Mariani, K. Gunson, J. Jui [et al.] // Circulation. – 2009. – C. 663-670.
133. QT-interval abnormalities in hypertrophic cardiomyopathy / A. Dritsas, E. Sbarouni, D. Gilligan, P. Nihoyannopoulos, C. Oakley [et al.] // Clin Cardiol. – 1992. – C. 739-742.
134. Is QT dispersion associated with sudden cardiac death in patients with hypertrophic cardiomyopathy? / G. Yi, J. Poloniecki, S. Dickie, P. Elliott, M. Malik, W. McKenna [et al.] // Ann Noninvasive Electrocardiol. – 2001. – C. 209-215.
135. Impact of QT variables on clinical outcome of genotyped hypertrophic cardiomyopathy / K. Uchiyama, K. Hayashi, N. Fujino, T. Konno, Y. Sakamoto, K. Sakata, M. Kawashiri, H. Ino, M. Yamagishi [et al.] // Ann Noninvasive Electrocardiol. – 2009. – C. 65-71.
136. Familial hypertrophic cardiomyopathy associated with prolongation of the QT interval / S. Peters, H. Rust, M. Trummel, A. Brattstrom [et al.] // Z Kardiol. – 2000. – C. 624-629.
137. Abnormal QT interval variability in patients with hypertrophic cardiomyopathy: can syncope be predicted? / S. Cuomo, F. Marciano, M. Migaux, F. Finizio, E. Pezzella, M. Losi, S. Betocchi [et al.] // J Electrocardiol. – 2004. – C. 113-119.
138. Hypertrophic cardiomyopathy: electrical abnormalities detected by the extended-length ECG and their relation to syncope / G. Barletta, C. Lazzeri, F. Franchi, D. Bene, A. Michelucci [et al.] // Int J Cardiol Oct. – 2004. – C. 43-48.
139. QT dispersion and left ventricular morphology in patients with hypertrophic cardiomyopathy / K. Sakata, M. Shimizu, H. Ino, M. Yamaguchi, H. Terai, K. Hayashi, M. Kiyama, T. Hayashi, M. Inoue, H. Mabuchi [et al.] // Heart. – 2003. – C. 882-886.
140. The relationship between QT dispersion and risk factors of sudden death in hypertrophic cardiomyopathy / O. Goktekin, K. Ritsushi, K. Matsumoto, M. Hiroshi [et al.] // Anadolu Kardiyol Derg. – 2002. – C. 226-230.
141. Determinant of QT dispersion in patients with hypertrophic cardiomyopathy / T. Kawasaki, A. Azuma, T. Kuribayashi, H. Shiraishi, T. Sawada, H. Sugihara, M. Nakagawa [et al.] // Pacing Clin Electrophysiol. – 2003. – C. 819-826.
142. Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy / X. Jouven, A. Hagege, P. Charron, L. Carrier, O. Dubourg, J. Langlard, S. Aliaga, J. Bouhour, K. Schwartz, M. Desnos, M. Komajda [et al.] // Heart. – 2002. – C. 153-157.
143. QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy / G. Yi, P. Elliott, W. McKenna, K. Prasad, S. Sharma, X. Guo, A. Camm, M. Malik [et al.] // Am J Cardiol. – 1998. – C. 1514-1519.
144. Hamoudi A. Cirrhotic cardiomyopathy / A. Hamoudi, S. Lee // Ann Hepatol. – 2006. – № 5. – C. 132-139.
145. Baik S. Cirrhotic cardiomyopathy / S. Baik, T. Fouad, S. Lee // Orphanet J Rare Dis. – 2007. – № 2. – C. 15-15.
146. Podlesny M. Diabetic cardiomyopathy / M. Podlesny // Pol Merkur Lekarski. – 2003. – № 15(89). – C. 476-479.
147. Casis O. Diabetic cardiomyopathy: electromechanical cellular alterations / O. Casis, E. Echevarria // Curr Vasc Pharmacol. – 2004. – № 2. – C. 237-248.
148. Torsade de pointes associated with bradycardia and takotsubo cardiomyopathy / S. Kurisu, I. Inoue, T. Kawagoe, M. Ishihara, Y. Shimatani, Y. Nakama, K. Ohkawa, T. Maruhashi, E. Kagawa, K. Dai, T. Aokage [et al.] // Can J Cardiol. – 2008. – C. 640-642.
149. Repeated changes of electrocardiogram caused by Takotsubo-type cardiomyopathy: a case with hypertrophic nonobstructive cardiomyopathy / S. Miyoshi, Y. Hara, A. Ogimoto, Y. Shigematsu, T. Okura, J. Higaki [et al.] // Nippon Ronen Igakkai Zasshi. – 2005. – C. 112-115.
150. Stanescu C. Takotsubo cardiomyopathy / C. Stanescu, K. Branidou // Rom J Intern Med. – 2006. – № 44. – C. 97-9116.
151. Takotsubo cardiomyopathy as a potential cause of long QT syndrome and torsades de pointes / S. Ghosh, P. Apte, N. Maroz, A. Broor, N. Zeineh, I. Khan [et al.] // Int J Cardiol. – 2009. – C. 225-227.
152. Mahida S. Long-QT syndrome and torsades de pointes in a patient with Takotsubo cardiomyopathy: an unusual case / S. Mahida, C. Dalageorgou, E. Behr // Europace. – 2009. – № 11. – C. 376-378.
153. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes? / L. Samuelov-Kinori, M. Kinori, Y. Kogan, M. Swartzon, H. Shalev, D. Guy, F. Ferenidou, N. Mashav, B. Sadeh, L. Atzmony, O. Kliuk-Ben-Basat, A. Steinvil, D. Justo [et al.] // J Electrocardiol. – 2009. – C. 353-357.
154. Ryerson L. QT intervals in metabolic dilated cardiomyopathy / L. Ryerson, R. Giuffre // Can J Cardiol. – 2006. – № 22. – C. 217-220.
155. QT dispersion in nonischemic dilated cardiomyopathy. A long-term evaluation / L. Fauchier, J. Douglas, D. Babuty, P. Cosnay, J. Fauchier [et al.] // Eur J Heart Fail. – 2005. – C. 277-282.
156. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy / R. Berger, E. Kasper, K. Baughman, E. Marban, H. Calkins, G. Tomaselli [et al.] // Circulation. – 1997. – C. 1557-1565.
157. Electrocardiographic abnormalities and uremic cardiomyopathy / G. Stewart, R. Gansevoort, P. Mark, E. Rooney, T. McDonagh, H. Dargie, R. Stuart, C. Rodger, A. Jardine [et al.] // Kidney Int. – 2005. – C. 217-226.
158. QT interval dispersion in patients with chronic heart failure secondary to Chagas' cardiomyopathy: correlation with clinical variables of prognostic significance / H. Corbucci, D. Haber, R. Bestetti, J. Cordeiro, M. Fioroni [et al.] // Cardiovasc Pathol. – 2006. – C. 18-23.
159. The prolongation of the QT interval in the acute rheumatic carditis: an enigma / R. Lurildo, . Saraiva, L. Cleusa, I. Remigio [et al.] // Arq. Bras. Cardiol. – 2006. – C. 431-436.
160. The characteristics of myocarditis in diphtheria in adults based on data from the 1993-1994 epidemic / M. Reiderman, N. Astaf'eva, I. Bobrinskaia, A. Vorob'ev [et al.] // Ter Arkh. – 1996. – C. 61-63.
161. QT dispersion in acute rheumatic fever / T. Polat, Y. Yalcin, C. Akdeniz, C. Zeybek, A. Erdem, A. Celebi [et al.] // Cardiol Young. – 2006. – C. 141-146.
162. Boulmier D. Myocardial pseudo-infarction: "stress"-associated catecholamine-induced acute cardiomyopathy or coronary spasm? / D. Boulmier, P. Bazin // Ann Cardiol Angeiol. – 2000. – № 49. – C. 449-454.
163. Abnormal QT dispersion in Behcet's disease / O. Goldeli, D. Ural, B. Komsuoglu, A. Agacdiken, E. Dursun, B. Cetinarslan [et al.] // Int J Cardiol. – 1997. – C. 55-59.
164. Aguiar . Dispersao do intervalo QT na carditereumatica / . Aguiar, . MIR // Universidade Federal de Pernambuco. – 2004. – № 49. – C. 320-324.
165. QT dispersion and diastolic functions in differential diagnosis of primary mitral valve prolapse and rheumatic mitral valve prolapse / B. Guven, A. Eroglu, K. Babaoglu, T. Demir, A. Guzeltas, F. Oztunc, L. Saltik [et al.] // Pediatr Cardiol. – 2008. – C. 352-358.
166. Relation between QT dispersion and ventricular arrhythmias in uncomplicated isolated mitral valve prolapse / M. Ulgen, I. Biyik, A. Karadede, A. Temamogullari, S. Alan, N. Toprak [et al.] // Jpn Circ J. – 1999. – C. 929-933.
167. Increased dispersion of refractoriness in the absence of QT prolongation in patients with mitral valve prolapse and ventricular arrhythmias / R. Tieleman, H. Crijns, A. Wiesfeld, J. Posma, H. Hamer, K. Lie [et al.] // Br Heart J. – 1995. – C. 37-40.
168. The clinical significance of QTc dispersion measurement for risk of syncope in patients with aortic stenosis / F. Kosar, I. Tandogan, I. Hisar, Y. Aytan, M. Ileri [et al.] // J Interv Cardiol. – 2001. – C. 429-432.
169. Reduction of the QT interval dispersion after aortic valve replacement reflects changes in electrical function rather than structural remodeling / E. Orlowska-Baranowska, R. Baranowski, B. Kusmierczyk, J. Sepiska [et al.] // J Heart Valve Dis. – 2005. – C. 181-185.
170. QTc dispersion measurement for risk of syncope in patients with aortic stenosis / F. Kosar, I. Hisar, T. Durmaz, M. Ileri, I. Tandogan [et al.] // Angiology. – 2001. – C. 259-265.
171. Darbar D. QT dispersion is reduced after valve replacement in patients with aortic stenosis / D. Darbar, C. Cherry, D. Kerins // Heart. – 1999. – № 82. – C. 15-18.
172. Analysis of QT interval in patients with idiopathic mitral valve prolapse / S. Bekheit, A. Ali, S. Deglin, A. Jain [et al.] // Chest. – 1982. – C. 620-625.
173. ECG predictors of ventricular arrhythmias and biventricular size and wall mass in tetralogy of Fallot with pulmonary regurgitation / W. Helbing, A. Roest, R. Niezen, H. Vliegen, M. Hazekamp, J. Ottenkamp, d. Roos, v. der [et al.] // Heart. – 2002. – C. 515-519.
174. Electrophysiological changes following balloon valvuloplasty and angioplasty for aortic stenosis and coartaction of aorta: clinical evidence for mechano-electrical feedback in humans / B. Sarubbi, R. Calvanese, B. Cappelli, G. Santoro, R. Giovanna, R. Calabro [et al.] // Int J Cardiol. – 2004. – C. 7-11.
175. Influence of valve prosthesis type on the recovery of ventricular dysfunction and subendocardial ischaemia following valve replacement for aortic stenosis / J. Collinson, M. Flather, A. Coats, J. Pepper, M. Henein [et al.] // Int J Cardiol. – 2004. – C. 535-541.
176. Abnormalities of ventricular repolarization in mitral valve prolapse / S. Digeos-Hasnier, X. Copie, O. Paziaud, E. Abergel, L. Guize, B. Diebold, X. Jeunemaitre, A. Berrebi, O. Piot, T. Lavergne, L. Heuzey [et al.] // Ann Noninvasive Electrocardiol. – 2005. – C. 297-304.
177. Davey P. Prolongation of the QT interval in heart failure occurs at low but not at high heart rates / P. Davey, C. Barlow, G. Hart // Clinical science. – 2000. – № 5. – C. 603-610.
178. QT dispersion in patients with chronic heart failure: beta-blockers are associated with a reduction in QT dispersion / C. Bonnar, A. Davie, L. Caruana, L. Fenn, S. Ogston, J. McMurray, A. and [et al.] // Heart. – 1999. – C. 297-302.
179. QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities / P. Davey, J. Bateman, I. P, C. Forfar, C. Barlow, G. Hart [et al.] // British Heart Journal. – 1994. – C. 268-273.
180. QT interval disturbances in hospitalized elderly patients / E. Lubart, R. Segal, A. Yearovoi, A. Fridenson, Y. Baumoehl, A. Leibovitz [et al.] // Isr Med Assoc J. – 2009. – C. 147-150.
181. Prevalence of QTc prolongation in adult Nigerians with chronic heart failure / P. Kolo, O. Opadijo, A. Omotoso, M. Balogun, M. Araoye, I. Katibi [et al.] // West Afr J Med. – 2008. – C. 69-73.
182. Y . James Kang Cardiac Hypertrophy: A Risk Factor for QT-Prolongation and Cardiac Sudden Death / . Y // Toxicologic Pathology. – 2006. – № 34. – C. 58-66.
183. QTc interval prolongation predicts postoperative mortality in heart failure patients undergoing surgical revascularization / B. Vrtovec, A. Ryazdanbakhsh, T. Pintar, C. Collard, I. Gregoric, B. Radovancevic [et al.] // Tex Heart Inst J. – 2006. – C. 3-8.
184. Swynghedauw B. The long QT interval is not only inherited but is also linked to cardiac hypertrophy / B. Swynghedauw, C. Baillard, P. Milliez // J Mol Med. – 2003. – № 81. – C. 336-345.
185. Swynghedauw B. The acquired long QT during cardiac hypertrophy. Origin, incidence and significance / B. Swynghedauw // Bull Acad Natl Med. – 2005. – № 189. – C. 31-40.
186. Zareba K. Predictive value of admission electrocardiography in
patients with heart failure / K. Zareba, H. Shenkman, J. Bisognano // Congest Heart Fail. – 2008. – № 14. – C. 173-179.
187. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure / B. Vrtovec, R. Delgado, A. Zewail, C. Thomas, B. Richartz, B. Radovancevic [et al.] // Circulation Apr. – 2003. – C. 1764-1769.
188. Prognostic significance of QT interval prolongation in adult Nigerians with chronic heart failure / P. Kolo, O. Opadijo, A. Omotoso, I. Katibi, M. Balogun, M. Araoye [et al.] // Niger J Clin Pract Dec. – 2008. – C. 336-341.
189. Prognostic value of QT/RR slope in predicting mortality in patients with congestive heart failure / I. Cygankiewicz, W. Zareba, R. Vazquez, J. Almendral, A. Bayes-Genis, M. Fiol, M. Valdes, C. Macaya, J. Gonzalez-Juanatey, J. Cinca, d. Bayes [et al.] // J Cardiovasc Electrophysiol. – 2008. – C. 1066-1072.
190. QRS and QTc interval prolongation in the prediction of long-term mortality of patients with acute destabilised heart failure / T. Breidthardt, M. Christ, M. Matti, D. Schrafl, K. Laule, M. Noveanu, T. Boldanova, T. Klima, W. Hochholzer, A. Perruchoud, C. Mueller [et al.] // Heart. – 2008. – C. 508-509.
191. QT dynamicity: a prognostic factor for sudden cardiac death in chronic heart failure / A. Pathak, D. Curnier, J. Fourcade, J. Roncalli, P. Stein, P. Hermant, M. Bousquet, P. Massabuau, J. Senard, J. Montastruc, M. Galinier [et al.] // Eur J Heart Fail. – 2005. – C. 269-275.
192. QT intervals and QT dispersion determined from a 12-lead 24-hour Holter recording in patients with coronary artery disease and patients with heart failure / S. Hansen, V. Rasmussen, C. Torp-Pedersen, G. Jensen [et al.] // Ann Noninvasive Electrocardiol. – 2008. – C. 22-30.
193. QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy / L. Fei, J. Goldman, K. Prasad, P. Keeling, K. Reardon, A. Camm, W. McKenna [et al.] // Eur Heart J. – 1996. – C. 258-263.
194. Lack of diurnal variation of P-wave and QT dispersions in patients with heart failure / Y. Gunes, M. Tuncer, U. Guntekin, S. Akdag, H. Gumrukcuoglu [et al.] // Pacing Clin Electrophysiol. – 2008. – C. 974-978.
195. Kautzner J. QT interval dispersion and its clinical utility / J. Kautzner, M. Malik // Pacing Clin Electrophysiol. – 1997. – № 20. – C. 2625-2640.
196. Basil M. ECG Abnormalities Associated With Hypocalcemia / M. Basil, . RuDusky // Chest journal. – 2001. – № 8. – C. 239-242.
197. Christopher B. Hypocalcemia / B. Christopher // Emergency Medicine. – 2009. – № 5. – C. 531-535.
198. The QT Interval and Serum Ionized Calcium / W. Rumancik, J. Denlinger, L. Michael, B. Robert [et al.] // JAMA. – 1978. – C. 366-368.
199. Cubeddu L. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs / L. Cubeddu // Am J Ther. – 2003. – № 10. – C. 452-457.
200. Roden D. Drug-induced prolongation of the QT interval / D. Roden // N Engl J Med. – 2004. – № 3511. – C. 1013-1022.
201. Bisinov E. FACC Potassium andlong QT syndrome / E. Bisinov, H. James, T. Craig // J Am Coll Cardiol. – 2003. – № 42. – C. 1783-1784.
202. Prolongation of the QT interval in primary aldosteronism / K. Matsumura, K. Fujii, Y. Kansui, H. Arima, M. Iida [et al.] // Clinical and Experimental Pharmacology and Physiology. – 2008. – C. 66-69.
203. Vorchheimer D. What is QT interval prolongation? / D. Vorchheimer // Journal of Family Practice. – 2005. – № 6. – C. 84-89.
204. Аритмии сердца : в 3 т. / [ред. Мандела В. Дж.]. – Москва : “Медицина”, 1996.
205. Haigney M. Tissue magnesium levels and the arrhythmic substrate in humans / M. Haigney, R. Berger, S. Schulman // J Cardiovasc Electrophysiol. – 1997. – № 8. – C. 980-986.
206. The QT interval / M. Bednar, E. Harrigan, R. Anziano, A. Camm, J. Ruskin [et al.] // Prog Cardiovasc Dis. – 2001. – C. 1-45.
207. Surawicz B. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarization? / B. Surawicz // J Am Coll Cardiol. – 1989. – № 14. – C. 172-184.
208. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans / W. Schmeling, D. Warltier, D. McDonald, K. Madsen, J. Atlee, J. Kampine [et al.] // Anesth Analg. – 1991. – C. 137-144.
209. The effects of volatile anesthetics on the QTc interval / N. Guler, I. Kati, C. Demirel, M. Bilge, B. Eryonucu, C. Topal [et al.] // J Cardiothorac Vasc Anesth. – 2001. – C. 188-191.
210. Anaesthesia and the QT interval in humans: effects of halothane and isoflurane in premedicated children / D. Michaloudis, O. Fraidakis, T. Lefaki, F. Kanakoudis, H. Askitopoulou [et al.] // Eur J Anaesthesiol. – 1998. – C. 623-628.
211. Doig J. Drug-induced cardiac arrhythmias: incidence, prevention, and management / J. Doig // Drug Saf. – 1997. – № 17. – C. 265-275.
212. Thomas S. Drugs, QT interval abnormalities and ventricular arrhythmias / S. Thomas // Adverse Drug React Toxciol Rev. – 1994. – № 13. – C. 77-7102.
213. Viskin S. Long QT syndromes and torsades de pointes / S. Viskin // Lancet. – 1999. – № 354. – C. 1625-1633.
214. Cardiac T. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction / T. Cardiac // N Engl J Med. – 1989. – № 321. – C. 406-412.
215. Maghurabi R. Tambocor (flecainide) use experience / R. Maghurabi // Drugs. – 1987. – № 17. – C. 22-24.
216. The proarrhythmic effects of flecainide / A. Nathan, K. Hellestrand, R. Bexton, R. Spurrell, A. Camm [et al.] // Drugs. – 1985. – C. 45-53.
217. Compared effects of sotalol, flecainide and propafenone on ventricular repolarization in patients free of underlying structural heart disease / B. Sarubbi, V. Ducceschi, N. Briglia, M. Mayer, L. Santangelo, A. Iacono [et al.] // Int J Cardiol. – 1998. – C. 157-164.
218. Day C. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals / C. Day, J. McComb, R. Campbell // Br Heart J. – 1990. – № 63. – C. 342-344.
219. Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle / D. Katritsis, E. Rowland, S. O'Nunain, C. Shakespeare, J. Poloniecki, A. Camm [et al.] // Eur Heart J. – 1995. – C. 1930-1935.
220. Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly? / R. Rocha, G. Silva, E. Perin, A. Gerk, E. Gouvea, V. Santos, F. Filho, d. Albuquerque [et al.] // Eur Heart J. – 1997. – C. 460-463.
221. Effect of nebivolol on QT dispersion in hypertensive patients with left ventricular hypertrophy / F. Galetta, F. Franzoni, A. Magagna, F. Femia, F. Pentimone, G. Santoro, A. Carpi [et al.] // Biomed Pharmacother. – 2005. – C. 15-19.
222. Effects of metoprolol on QT interval and QT dispersion in Type 1 diabetic patients with abnormal albuminuria / E. Ebbehoj, H. Arildsen, K. Hansen, C. Mogensen, H. Molgaard, P. Poulsen [et al.] // Diabetologia. – 2004. – C. 1009-1015.
223. Effect of atenolol on QTc interval lengthening during hypoglycaemia in type 1 diabetes / S. Lee, N. Harris, R. Robinson, C. Davies, R. Ireland, I. Macdonald, S. Heller [et al.] // Diabetologia. – 2005. – C. 1269-1272.
224. Effect of atenolol on QT interval and dispersion in patients with syndrome X / F. Leonardo, G. Fragasso, G. Rosano, P. Pagnotta, S. Chierchia [et al.] // Am J Cardiol. – 1997. – C. 789-790.
225. Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil / Y. Yoshiga, A. Shimizu, T. Yamagata, T. Hayano, T. Ueyama, M. Ohmura, K. Itagaki, M. Kimura, M. Matsuzaki [et al.] // Circ J. – 2002. – C. 1024-1028.
226. Farhangi V. QTc prolongation due to propranolol overdose / V. Farhangi, R. Sansone // Int J Psychiatry Med. – 2003. – № 33. – C. 201-202.
227. Hohnloser S. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management / S. Hohnloser // Am J Cardiol. – 1997. – № 80. – C. 82-89.
228. Soyka L. Clinical safety profile of sotalol in patients with arrhythmia / L. Soyka, C. Wirtz, R. Spengenburg // Am J Cardiol. – 1990. – № 65. – C. 74-81.
229. Hohnloser S. Incidence, type, and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF / S. Hohnloser, W. Arendts, B. Quart // Pacing Clin Electrophysiol. – 1992. – № 15. – C. 173-173.
230. Sex differences in risk of torsades de pointes with d,l sotalol / M. Lehmann, S. Hardy, D. Archibald, B. Quart, D. MacNeil [et al.] // Circulation. – 1996. – C. 2534-2541.
231. Hohnloser S. Amiodarone-associated proarrhythmic effects: a review with special reference to torsades de pointes tachycardia / S. Hohnloser, T. Klingenheben, B. Singh // Ann Intern Med. – 1994. – № 121. – C. 529-535.
232. Jafari-Fesharaki M. Adverse effects of amiodarone / M. Jafari-Fesharaki, M. Scheinman // Pacing Clin Electrophysiol. – 1998. – № 21. – C. 108-120.
233. Howard P. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter / P. Howard // Ann Pharmacother. – 1999. – № 33. – C. 38-47.
234. Pedersen H. DIAMOND Study Group. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide / H. Pedersen, H. Elming, M. Seibaek // Am J Cardiol. – 2007. – № 100. – C. 876-880.
235. Crouch . Drug-Related QT Interval Prolongation: Drugs Associated with QT Prolongation / . Crouch, . Limon, . Cassano // Pharmacotherapy. – 2003. – № 23. – C. 17-20.
236. HERG and KvLQT1/IsK, the cardiac K[+] channels involved in long QT syndromes, are targets for calcium channel blockers / C. Chouabe, M. Driel, G. Romey, J. Barhanin, M. Lazdunski [et al.] // Mol Pharmacol. – 1998. – C. 695-703.
237. Electrocardiographic effects of probucol: a controlled prospective clinical trial / C. Dujovne, F. Atkins, B. Wong, S. DeCoursey, P. Krehbiel, S. Chernoff [et al.] // Eur J Clin Pharmacol. – 1984. – C. 735-739.
238. Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug / K. Browne, E. Prystowsky, J. Heger, B. Cerimele, N. Fineberg, D. Zipes [et al.] // Am Heart J. – 1984. – C. 680-684.
239. Crome P. Antidepressant overdosage / P. Crome // Drugs. – 1982. – № 23. – C. 431-461.
240. Thorstrand C. Clinical features in poisonings by tricyclic antidepressants with special reference to the ECG / C. Thorstrand // Acta Medica Scandinavica. – 1976. – № 199. – C. 337-344.
241. Herrmann H. QT prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline / H. Herrmann, L. Kaplan, B. Bierer // Am J Cardiol. – 1983. – № 81. – C. 904-906.
242. Leonard H. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents / H. Leonard, M. Meyer, S. Swedo // J Am Acad Child Adolesc Psychiatry. – 1995. – № 34. – C. 1460-1468.
243. Biederman J. A naturalistic study of 24-hour electrocardiographic findings in children and adolescents treated with desipramine / J. Biederman, R. Baldessarini, A. Goldblatt // J Am Acad Child Adolesc Psychiatry. – 1993. – № 32. – C. 805-813.
244. Riddle M. Another sudden death in a child with desipramine / M. Riddle, B. Geller, N. Ryan // J Am Acad Child Adolesc Psychiatry. – 1993. – № 32. – C. 792-797.
245. Baker B. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder / B. Baker, P. Dorian, P. Sandon // J Clin Psychopharmacol. – 1997. – № 17. – C. 15-21.
246. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline / A. Teschemacher, E. Seward, J. Hancox, H. Witchel [et al.] // Br J Pharmacol. – 1999. – C. 479-485.
247. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects: is there any? / P. Pacher, Z. Ungvari, P. Nanasi, S. Furst, V. Keeskemeti [et al.] // Curr Med Chem. – 1999. – C. 469-480.
248. ECG changes after paroxetine: 3 case reports / A. Erfurth, M. Loew, P. Dobmeier, G. Wendler [et al.] // Nervenarzt. – 1998. – C. 629-631.
249. Sudden cardiac death with clozapine and sertraline combination / J. Hoehns, M. Fouts, M. Kelly, T. KB [et al.] // Ann Pharmacother. – 2001. – C. 862-866.
250. Beelen A. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone / A. Beelen, K. Yeo, L. Lewis // Hum Exp Toxicol. – 2001. – № 20. – C. 215-219.
251. Torsades de pointes occurring in association with terfenadine use / B. Monahan, C. Ferguson, E. Killeavy, B. Lloyd, J. Troy, L. Cantilena [et al.] // JAMA. – 1990. – C. 2788-2790.
252. Zimmermann M. Torsades de pointes after treatment with terfenadine and ketoconazole / M. Zimmermann, H. Duruz, O. Guinand // Eur Heart J. – 1992. – № 13. – C. 1002-1003.
253. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin / P. Honig, R. Woosley, K. Zamani, D. Conner, L. Cantilena [et al.] // Clin Pharmacol Ther. – 1992. – C. 231-238.
254. Clark A. Astemizole-induced ventricular arrhythmias: an unexpected case of convulsions / A. Clark, H. Love // Int J Cardiol. – 1991. – № 33. – C. 165-167.
255. Cardiotoxic effects of astemizole overdose in children / J. Wiley, M. Gelber, F. Henretig, C. Wiley, S. Sandhu, J. Loiselle [et al.] // J Pediatr. – 1992. – C. 799-802.
256. Berul C. Regulation of potassium channels by nonsedating antihistamines / C. Berul, M. Morad // Circulation. – 1995. – № 91. – C. 2220-2225.
257. Electrocardiographic findings in patients with diphenhydramine overdose / W. Zareba, A. Moss, S. Rosero, R. Hajj-Ali, J. Konecki, M. Andrews [et al.] // Am J Cardiol. – 1997. – C. 1168-1173.
258. Electro-physiological mechanisms in a canine model of erythromycin-associated long QT syndrome / M. Rubart, M. Pressler, H. Pride, D. Zipes [et al.] // Circulation. – 1993. – C. 1832-1844.
259. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature / S. Tschida, D. Guay, R. Straka, L. Hoey, R. Johanning, K. Vance-Bryan [et al.] // Pharmacotherapy. – 1996. – C. 663-674.
260. A review of erythromycin-induced malignant tachyarrhythmia- torsades de pointes: a case report / K. Katapadi, G. Kostandy, M. Katapadi, K. Hussain, D. Schifter [et al.] // Angiology. – 1997. – C. 821-826.
261. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism / S. Nattel, S. Ranger, M. Talajic, R. Lemery, D. Roy [et al.] // Am J Med. – 1990. – C. 235-238.
262. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de points / B. Darpo // Eur Heart J. – 2001. – № 3. – C. 70-80.
263. McComb J. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin / J. McComb, N. Campbell, J. Cleland // Am J Cardiol. – 1984. – № 54. – C. 922-923.
264. Rezkalla M. Erythromycin induced torsades de pointes: case report and review of the literature / M. Rezkalla, C. Pochop // S D J Med. – 1994. – № 47. – C. 161-164.
265. QT prolongation and recurrent 'torsades de pointes' during erythromycin administration / D. Guelon, B. Bedock, C. Chartier, J. Haberer [et al.] // Am J Cardiol. – 1986. – C. 666-666.
266. Gitler B. Torsades de pointes induced by erythromycin / B. Gitler, L. Berger, S. Buffa // Chest. – 1994. – № 105. – C. 368-372.
267. Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval / S. Chennareddy, M. Siddique, M. Karim, V. Kudesia [et al.] // Am Heart J. – 1996. – C. 691-694.
268. Cardiac actions of erythromycin: influence of female sex / M. Drici, B. Knollman, W. Wang, R. Woosley [et al.] // JAMA. – 1998. – C. 1774-1778.
269. QT prolongation and torsades de pointes associated with clarithromycin / K. Lee, M. Jim, S. Tang, Y. Tai [et al.] // Am J Med. – 1998. – C. 395-396.
270. QT prolonging drugs: mechanisms and clinical relevance of the arrhythmogenic hazards / M. Zehender, . Hohnloser, . S, H. Just [et al.] // Cardiovasc Drugs Ther. – 1991. – C. 515-530.
271. Shaffer D. Macrolide antibiotics and torsades de pointes postmarketing analysis / D. Shaffer, S. Singer // Telithromycin Advisory Committee. – 2001. – № 1. – C. 15-17.
272. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG / J. Kang, L. Wang, X. Chen, D. Triggle, D. Rampe [et al.] // Mol Pharmacol. – 2001. – C. 122-126.
273. Balfour J. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections / J. Balfour, H. Lamb // Drugs. – 2000. – № 59. – C. 115-139.
274. Sacks L. A review of the safety of moxifloxacin hydrochloride / L. Sacks // Drugs. – 2000. – № 24. – C. 59-63.
275. Dumaine R. Blockade of HERG and Kv1.5 by ketoconazole / R. Dumaine, M. Roy, A. Brown // J Pharmacol Exp Ther. – 1998. – № 286. – C. 727-735.
276. Paserchia L. Effects of ketoconazole on QTc [abstr] / L. Paserchia, J. Hewett, R. Woosley // Clin Pharmacol Ther. – 1994. – № 55. – C. 146-146.
277. Fluconazole-induced torsades-de pointes / V. Tholakanahalli, A. Potti, J. Hanley, A. Merliss [et al.] // Ann Pharmacother. – 2001. – C. 432-434.
278. Wassman S. Long QT syndrome and torsades de pointes in a patient receiving fluconazole / S. Wassman, G. Nickenig, M. Bohm // Ann Intern Med. – 1999. – № 131. – C. 797-797.
279. Tie H. Inhibition of HERG potassium channels by the antimalarial agent halofantrine / H. Tie, B. Walker, C. Singleton // Br J Pharmacol. – 2000. – № 140. – C. 1967-1975.
280. Monlun E. Cardiac complications of halofantrine: a prospective study of 20 patients / E. Monlun, L. Metayer, S. Szwandt // Trans R Soc Trop Med Hyg. – 1995. – № 89. – C. 430-433.
281. White N. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria / N. White, S. Looareesuwan, D. Warrell // J Cardiovasc Pharmacol. – 1983. – № 5. – C. 173-175.
282. Martin E. Quinine may trigger torsades de pointes during astemizole therapy / E. Martin, K. Rogalski, J. Black // Pacing Clin Electrophysiol. – 1997. – № 20. – C. 2024-2025.
283. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients / P. Laothavorn, J. Karbwang, N. Bangchang, D. Bunnag, T. Harinasuta [et al.] // Southeast Asian J Trop Med Public Health. – 1992. – C. 51-54.
284. Nosten F. Cardiac effects of antimalarial treatment with halofantrine / F. Nosten, F. Kuile, C. Luxemburger // Lancet. – 1993. – № 341. – C. 1054-1056.
2. Priori S. Task force on sudden cardiacdeath of the European society of cardiology / S. Priori, E. Aliot, C. Blomstrom-Lundqvist // EurHeart J. – 2001. – № 22. – C. 1374-1450.
3. Philippe M. Short QT syndrome. Update on a recent entity / M. Philippe, F. Extramiana, P. Sbragia // Archives of Cardiovascular Disease. – 2008. – № 101. – C. 779-786.
4. QT interval as a cardiac risk factor in a middleaged population / J. Karjalainen, A. Reunanen, P. Ristola, M. Viitasalo [et al.] // Heart. – 1997. – C. 543-548.
5. QT interval variables from 24 hour electrocardiography and the two-year risk of sudden death / A. Algra, J. Tijssen, J. Roelandt, J. Pool, J. Lubsen [et al.] // Br Heart J. – 1993. – C. 43-48.
6. Idiopathic short QT interval: a new clinical syndrome? / I. Gussak, P. Brugada, J. Brugada, R. Wright, S. Kopecky, B. Chaitman [et al.] // Cardiology. – 2000. – C. 99-9102.
7. Gaita F. Short QT syndrome. A familial cause of sudden death / F. Gaita, C. Giustetto, F. Bianchi // Circulation. – 2003. – № 108. – C. 965-970.
8. Wojciech Z. Long QT Syndrome and Short QT Syndrome / Z. Wojciech // Progress in Cardiovascular Diseases. – 2008. – № 3. – C. 264-278.
9. Priori S. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene / S. Priori, S. Pandit, I. Rivolta // Circ Res. – 2005. – № 96. – C. 800-807.
10. Bellocq C. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome / C. Bellocq, V. Ginneken, C. Bezzina // Circulation. – 2004. – № 109. – C. 2394-2397.
11. Short QT interval syndrome: a case report / A. Kirilmae, R. Uluso, E. Kardesoglu, N. Ozmen, E. Demilrap [et al.] // J Electrocardiol. – 2005. – C. 371-374.
12. Short QT Syndrome. Should we push the frontier forward? / P. Maury, L. Hollington, A. Duparc, R. Brugada [et al.] // Heart Rhythm. – 2005. – C. 1135-1137.
13. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2 / K. Hong, P. Bjerregaard, I. Gussak, R. Brugada [et al.] // J Cardiovasc Electrophysiol. – 2005. – C. 394-396.
14. Hong K. De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero / K. Hong, D. Piper, A. Diaz-Valdecantos // Cardiovasc Res. – 2005. – № 68. – C. 433-440.
15. Short QT syndrome: a case report and review of the literature / L. LX, W. Zhou, X. Zhang, Q. Cao, K. Yu, C. Zhu [et al.] // Resuscitation. – 2006. – C. 115-121.
16. Hiroto I. "Gender difference in QTc prolongation of people with mental disorders" / I. Hiroto, K. Toshiaki, I. Shigenobu // Annals of General Hospital Psychiatry. – 2004. – № 3. – C. 2832-2833.
17. Effects of Aging and Gender on QT Dispersion in an Overtly Healthy Population / J. Kassotis, C. Constantinos, K. Ashwani, T. Aneesh, J. Reiffel [et al.] // Pacing and Clinical Electrophysiology Volume. – 32. – C. 1121-1126.
18. Moss A. Long QT syndrome / A. Moss, J. Robinson // Heart Dis Stroke. – 1992. – № 1. – C. 309-314.
19. Goldenberg I. Moss, Wojciech Zareba / I. Goldenberg, J. Arthur // QT Interval: How to Measure It and What Is "Normal" Journal of Cardiovascular Electrophysiology. – 2006. – № 17. – C. 333-336.
20. Bazett H. An analysis of the time-relations of electrocardiograms" / H. Bazett // Heart. – 1920. – № 7. – C. 353-370.
21. Fridericia L. "The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease" / L. Fridericia // Acta Medica Scandinavica. – 1920. – № 53. – C. 469-486.
22. "An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)" / A. Sagie, M. Larson, R. Goldberg, J. Bengston, D. Levy [et al.] // Am J Cardiol. – 1992. – C. 797-801.
23. Donger C. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome / C. Donger, I. Denjoy, M. Berthet // Circulation. – 1997. – № 96. – C. 2778-2781.
24. Paulussen A. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 / A. Paulussen, R. Gilissen, M. Armstrong // J Electrocardiol. – 2007. – № 57. – C. 251-258.
25. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome / M. Curran, I. Splawski, K. Timothy, G. Vincent, E. Green, M. Keating [et al.] // Cell. – 1995. – C. 795-803.
26. Wang Q. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome / Q. Wang, J. Shen, I. Splawski // Cell. – 1995. – № 80. – C. 805-811.
27. Splawski I. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 / I. Splawski, J. Shen, K. Timothy // Circulation. – 2000. – № 102. – C. 1178-1185.
28. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long Qt syndrome genetic testing / 7. Tester, M. Will, C. Haglund, M. Ackerman [et al.] // Heart Rhythm. – 2005. – C. 507-517.
29. Mutations in the hminK gene cause long QT syndrome and suppress IKs function / I. Splawski, M. Tristani-Friouzi, M. Lehman, M. Sanguinetti, M. Keating [et al.] // Nat Genet. – 1997. – C. 338-340.
30. Abbott G. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia / G. Abbott, F. Sesti, I. Splawski // Cell. – 1999. – № 97. – C. 175-187.
31. Hiroshi M. The QT syndromes: long and short / M. Hiroshi, W. Jiashin, P. Douglas // Lancet. – 2008. – № 372. – C. 750-763.
32. Plaster N. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome / N. Plaster, R. Tawil, M. Tristani-Firouzi // Cell. – 2001. – № 105. – C. 511-519.
33. Splawski I. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism / I. Splawski, K. Timothy, L. Sharpe // Cell. – 2004. – № 119. – C. 19-31.
34. Vatta M. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome / M. Vatta, M. Ackerman, B. Ye // Circulation. – 2006. – № 114. – C. 2104-2112.
35. Short QT syndrome and atria fibrillation caused by mutation in KCNH2 / K. Hong, P. Bjerregaard, I. Gussak, R. Brugada [et al.] // J Cardiovasc Electrophysiol. – 2005. – C. 394-396.
36. Hong K. De novo KCNQ1 mutation responsible for atrial fi lbrillation and short QT syndrome in utero / K. Hong, D. Piper, A. Diaz-Valdecantos // Cardiovasc Res. – 2005. – № 68. – C. 433-440.
37. Brugada R. Sudden death associated with short-QT syndrome linked to mutations in HERG / R. Brugada, K. Hong, R. Dumaine // Circulation. – 2004. – № 109. – C. 30-35.
38. Antzelevitch C. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death / C. Antzelevitch, G. Pollevick, J. Cordeiro // Circulation. – 2007. – № 115. – C. 442-449.
39. Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillation / S. Das, S. Makino, Y. Melman, M. Shea, S. Goyal, A. Rosenzweig, C. Macrae, P. Ellinor [et al.] // Heart Rhythm. – 2009. – C. 1146-1153.
40. N Engl J Med / S. Hohnloser, H. Crijns, v. Eickels, C. Gaudin, R. Page, C. Torp-Pedersen, S. Connolly [et al.] // . – 2009. – C. 668-678.
41. Novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation / T. Makiyama, M. Akao, S. Shizuta, T. Doi, K. Nishiyama, Y. Oka, S. Ohno, Y. Nishio, K. Tsuji, H. Itoh, T. Kimura, T. Kita, M. Horie [et al.] // J Am Coll Cardiol. – 2008. – C. 1326-1334.
42. mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation / B. Benito, R. Brugada, R. Perich, E. Lizotte, J. Cinca, L. Mont, A. Berruezo, J. Tolosana, X. Freixa, P. Brugada, J. Brugada [et al.] // Heart Rhythm. – 2008. – C. 1434-1440.
43. KCNQ1 mutation Q147R is associated with atrial fibrillation and prolonged QT interval / A. Lundby, L. Ravn, J. Svendsen, S. Olesen, N. Schmitt [et al.] // Heart Rhythm. – 2007. – C. 1532-1541.
44. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2 / K. Hong, P. Bjerregaard, I. Gussak, R. Brugada [et al.] // J Cardiovasc Electrophysiol. – 2005. – C. 394-396.
45. Short QT Syndrome: a familial cause of sudden death / F. Gaita, C. Giustetto, F. Bianchi, C. Wolpert, R. Schimpf, R. Riccardi, S. Grossi, E. Richiardi, M. Borggrefe [et al.] // Circulation. – 2003. – C. 965-970.
46. Friedman P. Sotalol and a Broken Heart / P. Friedman, S. Montgomery, N. Matas // J Cardiovasc Electrophysiol. – 2009. – № 28. – C. 149-154.
47. Quinidine for pharmacological cardioversion of atrial fibrillation: a retrospective analysis in 501 consecutive patients / B. Schwaab, A. Katalinic, U. Boge, J. Loh, P. Blank, T. Kolzow, D. Poppe, H. Bonnemeier [et al.] // Ann Noninvasive Electrocardiol. – 2009. – C. 128-136.
48. Nibentan in arresting acute atrial fibrillation: risk or benefit? / A. Chapurnykh, O. Solov'ev, A. Zavalin, E. Pavlov, D. Efremov [et al.] // Ter Arkh. – 2008. – C. 41-45.
49. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome / D. Darbar, J. Kimbrough, A. Jawaid, R. McCray, M. Ritchie, D. Roden [et al.] // J Am Coll Cardiol. – 2008. – C. 836-842.
50. Long QT syndrome induced by cordaron and quinidine / E. Mironchik, T. Dolgoshei, T. Liskovich, G. Madeshkina, A. Kokhkovski, A. Tyshchenko [et al.] // Klin Med (Mosk). – 2007. – C. 69-71.
51. Nagra B. Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale / B. Nagra, G. Ledley, B. Kantharia // J Cardiovasc Pharmacol Ther. – 2005. – № 10. – C. 191-195.
52. Singh S. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study / S. Singh // Card Electrophysiol Rev. – 2003. – № 7. – C. 225-228.
53. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome / A. Ricardo, P. Riera, A. Hiroshi, C. Ferreira, C. Ferreira, E. Schapachnik, S. Dubner, L. Zhang [et al.] // Cardiol J. – 2008. – C. 209-219. Shantsila E. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias / E. Shantsila, W. Timothy, Y. Gregory // Europace. – 2007. – № 9. – C. 37-44.
54. Gupta A. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes / A. Gupta, A. Lawrence, K. Krishnan // Am Heart J. – 2007. – № 153. – C. 891-899.
55. Thomas D. Modulation of HERG potassium channel function by drug action / D. Thomas, C. Karle, J. Kiehn // Ann Med. – 2004. – № 36. – C. 41-46.
56. Selzer A. Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias / A. Selzer, H. Wray // Circulation. – 1964. – № 30. – C. 17-26.
57. Wolbrette D. Risk of proarrhythmia with class III antiarrhythmic agents: Sex-based differences and other issues / D. Wolbrette // Am J Cardiol. – 2003. – № 91. – C. 39-44.
58. Singh B. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs / B. Singh, N. Wadhani // J Cardiovasc Pharmacol Ther. – 2004. – № 9. – C. 85-97.
59. Antonaccio M. Encainide / M. Antonaccio, A. Gomoll, J. Byrne // Cardiovasc Drugs Ther. – 1989. – №3. – C. 691-710.
60. Antonaccio M. Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol / M. Antonaccio, A. Gomoll // Am J Cardiol. – 1993. – № 72. – C. 27-37.
61. Fitton A. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias / A. Fitton, E. Sorkin // Drugs. – 1993. – № 46. – C. 678-719.
62. Singh B. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent / B. Singh // Am J Cardiol. – 1996. – № 78. – C. 41-53.
63. Torsades de pointes ventricular tachycardia induced by intravenous amiodarone / A. Makai, L. Rudas, G. Liszkai, T. Fazekas [et al.] // Orv Hetil. – 2003. – C. 241-247.
64. Roukoz H. Dofetilide: a new class III antiarrhythmic agent / H. Roukoz, W. Saliba // Expert Rev Cardiovasc Ther. – 2007. – № 5. – C. 9-19.
65. Saliba W. Dofetilide (Tikosyn): a new drug to control atrial fibrillation / W. Saliba // Cleve Clin J Med. – 2001. – № 68. – C. 353-363.
66. Short QT Interval and Atrial Fibrillation in Patients Without Structural Heart Disease / G. Poglajen, M. Fister, B. Radovancevic, B. Vrtovec [et al.] // J Am Coll Cardiol. – 2006. – C. 1905-1907.
67. Pai G. The QT interval in atrial fibrillation / G. Pai, J. Rawles // Br Heart J. – 1989. – № 61. – C. 510-513.
68. Pai R. Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction / R. Pai, P. Varadarajan // Clin Cardiol. – 2007. – № 30. – C. 349-354.
69. Beat-to-beat QT dynamics in paroxysmal atrial fibrillation / C. Larroude, B. Jensen, E. Agner, E. Toft, C. Torp-Pedersen, K. Wachtell, J. Kanters [et al.] // Heart Rhythm. – 2006. – C. 660-664.
70. Comparison of QT dispersion during atrial fibrillation and sinus rhythm in the same patients, at normal and prolonged ventricular repolarization / B. Houltz, B. Darpo, K. Swedberg, P. Blomstrom, H. Crijns, S. Jensen, E. Svernhage, N. Edvardsson [et al.] // Europace. – 2000. – C. 20-31.
71. Soler-Soler J. QT dispersion after myocardial infarction with heart failure: additional prognostic marker? / J. Soler-Soler, E. Galve // European Heart Journal. – 1999. – № 20. – C. 1146-1148.
72. QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure / K. Spargias, S. Lindsay, G. Kawar, D. Greenwood, J. Cowan, S. Ball, A. Hall [et al.] // European Heart Journal. – 1999. – C. 1158-1165.
73. Roeinton B. The QT interval in myocardial infarction / B. Roeinton, . Khambaita, . MB // British Medical Journal. – 1953. – № 54. – C. 132-135.
74. QT Intervals in Acute Myocardial Infarction: First-Year Prognostic Implications / S. Ahnvem, C. Helmers, T. Lundmanm, D. Rehnqvistm, D. Sjogren [et al.] // Clin Cardiol. – 1980. – C. 303-308.
75. Higham P. QT dispersion and components of the QT interval in ischaemia and infarction / P. Higham, S. Furniss, R. Campbell // Br Heart J. – 1995. – № 73. – C. 32-36.
76. Use of lead adjustment formulas for QT dispersion after myocardial infarction / J. Glancy, C. Garratt, K. Woods, d. Bono [et al.] // Br Heart J. – 1995. – C. 676-679.
77. QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population / M. Manttari, L. Oikarinen, V. Manninen, M. Viitasalo [et al.] // Heart. – 1997. – C. 268-272.
78. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: results of a prospective, long-term follow-up study / M. Zabel, T. Klingenheben, M. Franz, S. Hohnloser [et al.] // Circulation. – 1998. – C. 2543-2550.
79. QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure / K. Spargias, S. Lindsay, G. Kawar, D. Greenwood, J. Cowan, S. Ball, A. Hall [et al.] // Eur Heart J. – 1999. – C. 1158-1165.
80. Predictive power of increased QT dispersion in ventricular extrasystoles and in sinus beats for risk stratification after myocardial infarction / A. Dabrowski, E. Kramarz, R. Piotrowicz, L. Kubik [et al.] // Circulation. – 2000. – C. 1693-1697.
81. Aitchison J. Time dependent variability of QT dispersion after acute myocardial infarction and its relation to ventricular fibrillation: a prospective study / J. Aitchison, R. Campbell, P. Higham // Heart. – 2000. – № 84. – C. 504-508.
82. Transient QT interval prolongation with inverted T waves indicates myocardial salvage on dual radionuclide single-photon emission computed tomography in acute anterior myocardial infarction / T. Obayashi, T. Tokunaga, T. Iiizumi, T. Shiigai, M. Hiroe, F. Marumo [et al.] // Jpn Circ J. – 2001. – C. 7-10.
83. Effects of depression on QT interval variability after myocardial infarction / R. Carney, K. Freedland, P. Stein, L. Watkins, D. Catellier, A. Jaffe, V. Yeragani [et al.] // Psychosom Med. – 2003. – C. 177-180.
84. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients / T. Clayton, J. Lubsen, S. Pocock, Z. Voko, B. Kirwan, K. Fox, P. Poole-Wilson [et al.] // BMJ. – 2005. – C. 869-869.
85. Methods of assessment and clinical relevance of QT dynamics / B. Sredniawa, A. Musialik-Lydka, P. Jarski, A. Sliwinska, Z. Kalarus [et al.] // Indian Pacing Electrophysiol J. – 2005. – C. 221-232.
86. QT interval dispersion analysis in acute myocardial infarction patients: coronary reperfusion effect / N. Lopes, C. Grupi, C. Dina, d. Gois, L. Hajjar, B. Ayub, C. Rochitte, J. Ramires, W. Hueb, R. Kalil [et al.] // Arq Bras Cardiol. – 2006. – C. 91-98.
87. Corrected QT interval prolongation: a new predictor of cardiovascular risk in patients with non-ST-elevation acute coronary syndrome / F. Gadaleta, S. Llois, V. Sinisi, J. Quiles, P. Avanzas, J. Kaski [et al.] // Rev Esp Cardiol Jun. – 2008. – C. 572-578.
88. Prominent negative T waves with QT prolongation indicate reperfusion injury and myocardial stunning / Y. Hirota, Y. Kita, R. Tsuji, H. Handa, K. Ishii, Y. Yoneda [et al.] // J Cardiol. – 1992. – C. 325-340.
89. Schwartz P. QT interval prolongation as predictor of sudden cardiac death in patients with myocardial infarction / P. Schwartz, S. Wolf // Circulation. – 1978. – № 57. – C. 1074-1077.
90. QTc interval in acute myocardial infarction: First-year prognostic implications / S. Ahnve, C. Helmers, T. Lundman, N. Rehqvist, A. Sjogren [et al.] // Clin Cardiol. – 1980. – C. 303-308.
91. Relationship between infarction location and size to QT dispersion in patients with chronic myocardial infarction / N. Hashimoto, H. Musha, A. Ozawa, Y. Imai, K. Kawasaki, O. Miyazu, J. Nagashima, T. So, F. Miyake, M. Murayama [et al.] // Jpn Heart J. – 2002. – C. 455-461.
92. Cavallini B. Dispersion of QT interval in arterial hypertension with left ventricular hypertrophy / B. Cavallini, V. Perri, M. Sali // Minerva Cardioangiol Jan-Feb. – 1996. – № 44(1-2). – C. 45-48.
93. QT-interval variability and autonomic control in hypertensive subjects with left ventricular hypertrophy / G. Piccirillo, G. Germano, R. Quaglione, M. Nocco, F. Lintas, M. Lionetti, A. Moise, M. Ragazzo, V. Marigliano, M. Cacciafesta [et al.] // Clin Sci (Lond). – 2002. – C. 363-371.
94. QT dispersion in relation to left ventricular geometry and hypertension in a population study / I. Pshenichnikov, T. Shipilova, J. Kaik, O. Volozh, J. Abina, J. Lass, D. Karai [et al.] // Scand Cardiovasc J. – 2003. – C. 87-90.
95. Left ventricular hypertrophy and QT interval in obesity and in hypertension: effects of weight loss and of normalisation of blood pressure / A. Pontiroli, P. Pizzocri, A. Saibene, A. Girola, D. Koprivec, G. Fragasso [et al.] // Int J Obes Relat Metab Disord. – 2004. – C. 1118-1123.
96. Increased myocardial repolarization lability and reduced cardiac baroreflex sensitivity in individuals with high-normal blood pressure / A. Myredal, S. Gao, P. Friberg, G. Jensen, L. Larsson, M. Johansson [et al.] // J Hypertens. – 2005. – C. 1751-1756.
97. Importance of the electrocardiographic strain pattern in patients with resistant hypertension / G. Salles, C. Cardoso, A. Nogueira, K. Bloch, E. Muxfeldt [et al.] // Hypertension. – 2006. – C. 437-442.
98. Nunes J. Cardiac structure and apnea/hypopnea index in patients with arterial hypertension and excessive weight / J. Nunes, N. Oliveira // Kidney Blood Press Res. – 2006. – № 29. – C. 159-164.
99. Relationship of electrocardiographic repolarization measures to
echocardiographic left ventricular mass in men with hypertension / K. Porthan, J. Virolainen, T. Hiltunen, M. Viitasalo, H. Vaananen, J. Dabek, T. Hannila-Handelberg, L. Toivonen, M. Nieminen, K. Kontula, L. Oikarinen [et al.] // J Hypertens. – 2007. – C. 1951-1957.
100. QT interval prolongation among patients treated with angiogenesis inhibitors / S. Ederhy, A. Cohen, G. Dufaitre, H. Izzedine, C. Massard, C. Meuleman, B. Besse, E. Berthelot, F. Boccara, J. Soria [et al.] // Target Oncol. – 2009. – C. 89-97.
101. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens / H. Elming, E. Holm, L. Jun, C. Torp-Pedersen, L. Kober, M. Kircshoff, M. Malik, J. Camm [et al.] // Eur Heart J Sep. – 1998. – C. 1391-1400.
102. Autonomic modulation and QT interval dispersion in hypertensive subjects with anxiety / G. Piccirillo, E. Viola, M. Nocco, E. Santagada, M. Durante, C. Bucca, V. Marigliano [et al.] // Hypertension. – 1999. – C. 242-246.
103. Rekiene D. JTc prolongation in hypertrophic cardiomyopathy amd arterial hypertension / D. Rekiene // Medicina (Kaunas). – 2002. – № 38. – C. 1083-1085.
104. Importance of the electrocardiographic strain pattern in patients with resistant hypertension / G. Salles, C. Cardoso, A. Nogueira, K. Bloch, E. Muxfeldt [et al.] // Hypertension Sep. – 2006. – C. 437-442.
105. Relationship between the elastic properties of aorta and QT dispersion in newly diagnosed arterial adult hypertensives / M. Gur, R. Yilmaz, R. Demirbag, A. Yildiz, S. Akyol, M. Polat, M. Bas [et al.] // Anadolu Kardiyol Derg. – 2007. – C. 275-280.
106. Arterial hypertension, left ventricular geometry and QT dispersion in a middle-aged Estonian female population / T. Shipilova, I. Pshenichnikov, J. Kaik, O. Volozh, J. Abina, M. Kalev, J. Lass, D. Karai [et al.] // Blood Press. – 2003. – C. 12-18.
107. Prolonged ventricular repolarization measured by corrected QT interval (QTc) in subclinical hyperthyroidism / M. Owecki, A. Michalak, E. Nikisch, J. Sowinski [et al.] // Horm Metab Res. – 2006. – C. 44-47.
108. Hief C. Effect of enflurane on inducibility of ventricular tachycardia / C. Hief, M. Borggrefe, X. Chen // Am J Cardiol. – 1991. – № 68. – C. 609-613.
109. Circadian rhythmicity of rate-normalized QT interval in hypothyroidism and its significance for development of class III antiarrhythmic agents / J. Sarma, K. Venkataraman, P. Nicod, R. Polikar, J. Smith, M. Schoenbaum, B. Singh [et al.] // Am J Cardiol. – 1990. – C. 959-963.
110. QT/QS2 index in patients with arterial hypertension, mitral valve prolapse and hyperthyroidism / Z. Purzycki, M. Nowicki, J. Regula, L. Bieniaszewski, K. Zaborowski, T. Zdrojewski [et al.] // Pol Tyg Lek. – 1992. – C. 576-578.
111. Hyperthyroidism is associated with lengthening of ventricular repolarization / R. Colzani, M. Emdin, F. Conforti, C. Passino, M. Scarlattini, G. Iervasi [et al.] // Clin Endocrinol (Oxf). – 2001. – C. 27-32.
112. Prolonged ventricular repolarization measured by QTc interval in hyperthyroidism / M. Owecki, A. Michalak, E. Nikisch, J. Sowinski [et al.] // Pol Merkur Lekarski. – 2005. – C. 24-27.
113. Nowak J. Influence of hyperthyroidism defined as TSH serum level on QT corrected interval dispersion (QTcd) / J. Nowak, J. Dubiel // Przegl Lek. – 2006. – № 63. – C. 123-127.
114. QTc dispersion in hyperthyroidism and its association with pulmonary hypertension / U. Guntekin, Y. Gunes, M. Tuncer, H. Simsek, H. Gumrukcuoglu, S. Arslan, A. Gunes [et al.] // Pacing Clin Electrophysiol. – 2009. – C. 494-499.
115. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women / d. Bacquer, d. Backer, M. Kornitzer, H. Blackburn [et al.] // Heart. – 1998. – C. 570-577.
116. Lehmann M. QT interval: metric for cardiac prognosis? / M. Lehmann, F. Morady // Am J Med. – 2003. – № 115. – C. 732-734.
117. Jimйnez-Candil J. QT Interval and Acute Myocardial Ischemia: Past Promises, New Evidences / J. Jimйnez-Candil, M. Cбndido // Rev Esp Cardiol. – 2008. – № 61. – C. 561-563.
118. Bijl M. Extreme QT prolongation solely due to reversible myocardial ischemia in single-vessel coronary disease / M. Bijl, F. Verheugt // Am Heart J. – 1992. – № 123. – C. 524-526.
119. Sredniawa B. Dispersion of the QT interval in unstable angina pectoris / B. Sredniawa, A. Musialik-Lydka, S. Pasyk // Pol Arch Med Wewn. – 2000. – № 103. – C. 41-45.
120. Furman N. Dynamics of QT interval dispersion in patients with ischemic heart disease during stress test as possible reflection of changes of terminal part of the T-wave / N. Furman, S. Shmatova, P. Dovgalevski // Kardiologiia. – 2007. – № 47. – C. 19-23.
121. Analysis of factors influencing QT interval dispersion in patients with stable angina / N. Furman, S. Shmatova, P. Dovgalevskii, M. Sham'iunov, V. Mukhortov [et al.] // Klin Med (Mosk). – 2009. – C. 20-23.
122. The effect of acute psychological stress on QT dispersion in patients with coronary artery disease / M. Hassan, A. Mela, Q. Li, B. Brumback, R. Fillingim, J. Conti, D. Sheps [et al.] // Pacing Clin Electrophysiol Sep. – 2009. – C. 1178-1183.
123. Higham P. QT dispersion and components of the QT interval in ischaemia and infarction / P. Higham, S. Furniss, R. Campbell // Br Heart J Jan. – 1995. – № 73. – C. 32-36.
124. Increased QT dispersion in patients with vasospastic angina / M. Suzuki, M. Nishizaki, M. Arita, T. Ashikaga, N. Yamawake, T. Kakuta, F. Numano, M. Hiraoka [et al.] // Circulation. – 1998. – C. 435-440.
125. Crow R. Prognostic significance of corrected QT and corrected JT interval for incident coronary heart disease in a general population sample stratified by presence or absence of wide QRS complex: the ARIC Study with 13 years of follow-up / R. Crow, P. Hannan, A. Folsom // Circulation. – 2003. – № 108(16). – C. 1985-1989.
126. QT interval dispersion: non-invasive marker of ischemic injury in patients with unstable angina pectoris? / O. Doven, C. Ozdol, T. Sayin, D. Oral [et al.] // Jpn Heart J Sep. – 2000. – C. 597-603.
127. Beat-to-beat QT interval variability associated with acute myocardial ischemia / T. Murabayashi, B. Fetics, D. Kass, E. Nevo, B. Gramatikov, R. Berger [et al.] // J Electrocardiol. – 2002. – C. 19-25.
128. Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary artery disease / R. Castro, G. Porphirio, S. Serra, A. Nobrega [et al.] // Braz J Med Biol Res. – 2002. – C. 685-689.
129. Effects of ischemia on repolarization in patients with single and multivessel coronary disease / D. Giedrimiene, S. Giri, A. Giedrimas, F. Kiernan, J. Kluger [et al.] // Pacing Clin Electrophysiol. – 2003. – C. 390-393.
130. Prolongation of the QTc interval is seen uniformly during early transmural ischemia / D. Kenigsberg, S. Khanal, M. Kowalski, S. Krishnan [et al.] // J Am Coll Cardiol. – 2007. – C. 1299-1305.
131. Relationship between the QTc interval at hospital admission and the severity of the underlying ischaemia in low and intermediate risk people studied for acute chest pain / J. Jimenez-Candil, M. Diego, C. Gonzalez, M. Gonzalez, F. Martin, P. Pabon, V. Ramirez, V. Leon, C. Martin-Luengo [et al.] // Int J Cardiol. – 2008. – C. 84-91.
132. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study / S. Chugh, K. Reinier, T. Singh, A. Uy-Evanado, C. Socoteanu, D. Peters, R. Mariani, K. Gunson, J. Jui [et al.] // Circulation. – 2009. – C. 663-670.
133. QT-interval abnormalities in hypertrophic cardiomyopathy / A. Dritsas, E. Sbarouni, D. Gilligan, P. Nihoyannopoulos, C. Oakley [et al.] // Clin Cardiol. – 1992. – C. 739-742.
134. Is QT dispersion associated with sudden cardiac death in patients with hypertrophic cardiomyopathy? / G. Yi, J. Poloniecki, S. Dickie, P. Elliott, M. Malik, W. McKenna [et al.] // Ann Noninvasive Electrocardiol. – 2001. – C. 209-215.
135. Impact of QT variables on clinical outcome of genotyped hypertrophic cardiomyopathy / K. Uchiyama, K. Hayashi, N. Fujino, T. Konno, Y. Sakamoto, K. Sakata, M. Kawashiri, H. Ino, M. Yamagishi [et al.] // Ann Noninvasive Electrocardiol. – 2009. – C. 65-71.
136. Familial hypertrophic cardiomyopathy associated with prolongation of the QT interval / S. Peters, H. Rust, M. Trummel, A. Brattstrom [et al.] // Z Kardiol. – 2000. – C. 624-629.
137. Abnormal QT interval variability in patients with hypertrophic cardiomyopathy: can syncope be predicted? / S. Cuomo, F. Marciano, M. Migaux, F. Finizio, E. Pezzella, M. Losi, S. Betocchi [et al.] // J Electrocardiol. – 2004. – C. 113-119.
138. Hypertrophic cardiomyopathy: electrical abnormalities detected by the extended-length ECG and their relation to syncope / G. Barletta, C. Lazzeri, F. Franchi, D. Bene, A. Michelucci [et al.] // Int J Cardiol Oct. – 2004. – C. 43-48.
139. QT dispersion and left ventricular morphology in patients with hypertrophic cardiomyopathy / K. Sakata, M. Shimizu, H. Ino, M. Yamaguchi, H. Terai, K. Hayashi, M. Kiyama, T. Hayashi, M. Inoue, H. Mabuchi [et al.] // Heart. – 2003. – C. 882-886.
140. The relationship between QT dispersion and risk factors of sudden death in hypertrophic cardiomyopathy / O. Goktekin, K. Ritsushi, K. Matsumoto, M. Hiroshi [et al.] // Anadolu Kardiyol Derg. – 2002. – C. 226-230.
141. Determinant of QT dispersion in patients with hypertrophic cardiomyopathy / T. Kawasaki, A. Azuma, T. Kuribayashi, H. Shiraishi, T. Sawada, H. Sugihara, M. Nakagawa [et al.] // Pacing Clin Electrophysiol. – 2003. – C. 819-826.
142. Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy / X. Jouven, A. Hagege, P. Charron, L. Carrier, O. Dubourg, J. Langlard, S. Aliaga, J. Bouhour, K. Schwartz, M. Desnos, M. Komajda [et al.] // Heart. – 2002. – C. 153-157.
143. QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy / G. Yi, P. Elliott, W. McKenna, K. Prasad, S. Sharma, X. Guo, A. Camm, M. Malik [et al.] // Am J Cardiol. – 1998. – C. 1514-1519.
144. Hamoudi A. Cirrhotic cardiomyopathy / A. Hamoudi, S. Lee // Ann Hepatol. – 2006. – № 5. – C. 132-139.
145. Baik S. Cirrhotic cardiomyopathy / S. Baik, T. Fouad, S. Lee // Orphanet J Rare Dis. – 2007. – № 2. – C. 15-15.
146. Podlesny M. Diabetic cardiomyopathy / M. Podlesny // Pol Merkur Lekarski. – 2003. – № 15(89). – C. 476-479.
147. Casis O. Diabetic cardiomyopathy: electromechanical cellular alterations / O. Casis, E. Echevarria // Curr Vasc Pharmacol. – 2004. – № 2. – C. 237-248.
148. Torsade de pointes associated with bradycardia and takotsubo cardiomyopathy / S. Kurisu, I. Inoue, T. Kawagoe, M. Ishihara, Y. Shimatani, Y. Nakama, K. Ohkawa, T. Maruhashi, E. Kagawa, K. Dai, T. Aokage [et al.] // Can J Cardiol. – 2008. – C. 640-642.
149. Repeated changes of electrocardiogram caused by Takotsubo-type cardiomyopathy: a case with hypertrophic nonobstructive cardiomyopathy / S. Miyoshi, Y. Hara, A. Ogimoto, Y. Shigematsu, T. Okura, J. Higaki [et al.] // Nippon Ronen Igakkai Zasshi. – 2005. – C. 112-115.
150. Stanescu C. Takotsubo cardiomyopathy / C. Stanescu, K. Branidou // Rom J Intern Med. – 2006. – № 44. – C. 97-9116.
151. Takotsubo cardiomyopathy as a potential cause of long QT syndrome and torsades de pointes / S. Ghosh, P. Apte, N. Maroz, A. Broor, N. Zeineh, I. Khan [et al.] // Int J Cardiol. – 2009. – C. 225-227.
152. Mahida S. Long-QT syndrome and torsades de pointes in a patient with Takotsubo cardiomyopathy: an unusual case / S. Mahida, C. Dalageorgou, E. Behr // Europace. – 2009. – № 11. – C. 376-378.
153. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes? / L. Samuelov-Kinori, M. Kinori, Y. Kogan, M. Swartzon, H. Shalev, D. Guy, F. Ferenidou, N. Mashav, B. Sadeh, L. Atzmony, O. Kliuk-Ben-Basat, A. Steinvil, D. Justo [et al.] // J Electrocardiol. – 2009. – C. 353-357.
154. Ryerson L. QT intervals in metabolic dilated cardiomyopathy / L. Ryerson, R. Giuffre // Can J Cardiol. – 2006. – № 22. – C. 217-220.
155. QT dispersion in nonischemic dilated cardiomyopathy. A long-term evaluation / L. Fauchier, J. Douglas, D. Babuty, P. Cosnay, J. Fauchier [et al.] // Eur J Heart Fail. – 2005. – C. 277-282.
156. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy / R. Berger, E. Kasper, K. Baughman, E. Marban, H. Calkins, G. Tomaselli [et al.] // Circulation. – 1997. – C. 1557-1565.
157. Electrocardiographic abnormalities and uremic cardiomyopathy / G. Stewart, R. Gansevoort, P. Mark, E. Rooney, T. McDonagh, H. Dargie, R. Stuart, C. Rodger, A. Jardine [et al.] // Kidney Int. – 2005. – C. 217-226.
158. QT interval dispersion in patients with chronic heart failure secondary to Chagas' cardiomyopathy: correlation with clinical variables of prognostic significance / H. Corbucci, D. Haber, R. Bestetti, J. Cordeiro, M. Fioroni [et al.] // Cardiovasc Pathol. – 2006. – C. 18-23.
159. The prolongation of the QT interval in the acute rheumatic carditis: an enigma / R. Lurildo, . Saraiva, L. Cleusa, I. Remigio [et al.] // Arq. Bras. Cardiol. – 2006. – C. 431-436.
160. The characteristics of myocarditis in diphtheria in adults based on data from the 1993-1994 epidemic / M. Reiderman, N. Astaf'eva, I. Bobrinskaia, A. Vorob'ev [et al.] // Ter Arkh. – 1996. – C. 61-63.
161. QT dispersion in acute rheumatic fever / T. Polat, Y. Yalcin, C. Akdeniz, C. Zeybek, A. Erdem, A. Celebi [et al.] // Cardiol Young. – 2006. – C. 141-146.
162. Boulmier D. Myocardial pseudo-infarction: "stress"-associated catecholamine-induced acute cardiomyopathy or coronary spasm? / D. Boulmier, P. Bazin // Ann Cardiol Angeiol. – 2000. – № 49. – C. 449-454.
163. Abnormal QT dispersion in Behcet's disease / O. Goldeli, D. Ural, B. Komsuoglu, A. Agacdiken, E. Dursun, B. Cetinarslan [et al.] // Int J Cardiol. – 1997. – C. 55-59.
164. Aguiar . Dispersao do intervalo QT na carditereumatica / . Aguiar, . MIR // Universidade Federal de Pernambuco. – 2004. – № 49. – C. 320-324.
165. QT dispersion and diastolic functions in differential diagnosis of primary mitral valve prolapse and rheumatic mitral valve prolapse / B. Guven, A. Eroglu, K. Babaoglu, T. Demir, A. Guzeltas, F. Oztunc, L. Saltik [et al.] // Pediatr Cardiol. – 2008. – C. 352-358.
166. Relation between QT dispersion and ventricular arrhythmias in uncomplicated isolated mitral valve prolapse / M. Ulgen, I. Biyik, A. Karadede, A. Temamogullari, S. Alan, N. Toprak [et al.] // Jpn Circ J. – 1999. – C. 929-933.
167. Increased dispersion of refractoriness in the absence of QT prolongation in patients with mitral valve prolapse and ventricular arrhythmias / R. Tieleman, H. Crijns, A. Wiesfeld, J. Posma, H. Hamer, K. Lie [et al.] // Br Heart J. – 1995. – C. 37-40.
168. The clinical significance of QTc dispersion measurement for risk of syncope in patients with aortic stenosis / F. Kosar, I. Tandogan, I. Hisar, Y. Aytan, M. Ileri [et al.] // J Interv Cardiol. – 2001. – C. 429-432.
169. Reduction of the QT interval dispersion after aortic valve replacement reflects changes in electrical function rather than structural remodeling / E. Orlowska-Baranowska, R. Baranowski, B. Kusmierczyk, J. Sepiska [et al.] // J Heart Valve Dis. – 2005. – C. 181-185.
170. QTc dispersion measurement for risk of syncope in patients with aortic stenosis / F. Kosar, I. Hisar, T. Durmaz, M. Ileri, I. Tandogan [et al.] // Angiology. – 2001. – C. 259-265.
171. Darbar D. QT dispersion is reduced after valve replacement in patients with aortic stenosis / D. Darbar, C. Cherry, D. Kerins // Heart. – 1999. – № 82. – C. 15-18.
172. Analysis of QT interval in patients with idiopathic mitral valve prolapse / S. Bekheit, A. Ali, S. Deglin, A. Jain [et al.] // Chest. – 1982. – C. 620-625.
173. ECG predictors of ventricular arrhythmias and biventricular size and wall mass in tetralogy of Fallot with pulmonary regurgitation / W. Helbing, A. Roest, R. Niezen, H. Vliegen, M. Hazekamp, J. Ottenkamp, d. Roos, v. der [et al.] // Heart. – 2002. – C. 515-519.
174. Electrophysiological changes following balloon valvuloplasty and angioplasty for aortic stenosis and coartaction of aorta: clinical evidence for mechano-electrical feedback in humans / B. Sarubbi, R. Calvanese, B. Cappelli, G. Santoro, R. Giovanna, R. Calabro [et al.] // Int J Cardiol. – 2004. – C. 7-11.
175. Influence of valve prosthesis type on the recovery of ventricular dysfunction and subendocardial ischaemia following valve replacement for aortic stenosis / J. Collinson, M. Flather, A. Coats, J. Pepper, M. Henein [et al.] // Int J Cardiol. – 2004. – C. 535-541.
176. Abnormalities of ventricular repolarization in mitral valve prolapse / S. Digeos-Hasnier, X. Copie, O. Paziaud, E. Abergel, L. Guize, B. Diebold, X. Jeunemaitre, A. Berrebi, O. Piot, T. Lavergne, L. Heuzey [et al.] // Ann Noninvasive Electrocardiol. – 2005. – C. 297-304.
177. Davey P. Prolongation of the QT interval in heart failure occurs at low but not at high heart rates / P. Davey, C. Barlow, G. Hart // Clinical science. – 2000. – № 5. – C. 603-610.
178. QT dispersion in patients with chronic heart failure: beta-blockers are associated with a reduction in QT dispersion / C. Bonnar, A. Davie, L. Caruana, L. Fenn, S. Ogston, J. McMurray, A. and [et al.] // Heart. – 1999. – C. 297-302.
179. QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities / P. Davey, J. Bateman, I. P, C. Forfar, C. Barlow, G. Hart [et al.] // British Heart Journal. – 1994. – C. 268-273.
180. QT interval disturbances in hospitalized elderly patients / E. Lubart, R. Segal, A. Yearovoi, A. Fridenson, Y. Baumoehl, A. Leibovitz [et al.] // Isr Med Assoc J. – 2009. – C. 147-150.
181. Prevalence of QTc prolongation in adult Nigerians with chronic heart failure / P. Kolo, O. Opadijo, A. Omotoso, M. Balogun, M. Araoye, I. Katibi [et al.] // West Afr J Med. – 2008. – C. 69-73.
182. Y . James Kang Cardiac Hypertrophy: A Risk Factor for QT-Prolongation and Cardiac Sudden Death / . Y // Toxicologic Pathology. – 2006. – № 34. – C. 58-66.
183. QTc interval prolongation predicts postoperative mortality in heart failure patients undergoing surgical revascularization / B. Vrtovec, A. Ryazdanbakhsh, T. Pintar, C. Collard, I. Gregoric, B. Radovancevic [et al.] // Tex Heart Inst J. – 2006. – C. 3-8.
184. Swynghedauw B. The long QT interval is not only inherited but is also linked to cardiac hypertrophy / B. Swynghedauw, C. Baillard, P. Milliez // J Mol Med. – 2003. – № 81. – C. 336-345.
185. Swynghedauw B. The acquired long QT during cardiac hypertrophy. Origin, incidence and significance / B. Swynghedauw // Bull Acad Natl Med. – 2005. – № 189. – C. 31-40.
186. Zareba K. Predictive value of admission electrocardiography in
patients with heart failure / K. Zareba, H. Shenkman, J. Bisognano // Congest Heart Fail. – 2008. – № 14. – C. 173-179.
187. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure / B. Vrtovec, R. Delgado, A. Zewail, C. Thomas, B. Richartz, B. Radovancevic [et al.] // Circulation Apr. – 2003. – C. 1764-1769.
188. Prognostic significance of QT interval prolongation in adult Nigerians with chronic heart failure / P. Kolo, O. Opadijo, A. Omotoso, I. Katibi, M. Balogun, M. Araoye [et al.] // Niger J Clin Pract Dec. – 2008. – C. 336-341.
189. Prognostic value of QT/RR slope in predicting mortality in patients with congestive heart failure / I. Cygankiewicz, W. Zareba, R. Vazquez, J. Almendral, A. Bayes-Genis, M. Fiol, M. Valdes, C. Macaya, J. Gonzalez-Juanatey, J. Cinca, d. Bayes [et al.] // J Cardiovasc Electrophysiol. – 2008. – C. 1066-1072.
190. QRS and QTc interval prolongation in the prediction of long-term mortality of patients with acute destabilised heart failure / T. Breidthardt, M. Christ, M. Matti, D. Schrafl, K. Laule, M. Noveanu, T. Boldanova, T. Klima, W. Hochholzer, A. Perruchoud, C. Mueller [et al.] // Heart. – 2008. – C. 508-509.
191. QT dynamicity: a prognostic factor for sudden cardiac death in chronic heart failure / A. Pathak, D. Curnier, J. Fourcade, J. Roncalli, P. Stein, P. Hermant, M. Bousquet, P. Massabuau, J. Senard, J. Montastruc, M. Galinier [et al.] // Eur J Heart Fail. – 2005. – C. 269-275.
192. QT intervals and QT dispersion determined from a 12-lead 24-hour Holter recording in patients with coronary artery disease and patients with heart failure / S. Hansen, V. Rasmussen, C. Torp-Pedersen, G. Jensen [et al.] // Ann Noninvasive Electrocardiol. – 2008. – C. 22-30.
193. QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy / L. Fei, J. Goldman, K. Prasad, P. Keeling, K. Reardon, A. Camm, W. McKenna [et al.] // Eur Heart J. – 1996. – C. 258-263.
194. Lack of diurnal variation of P-wave and QT dispersions in patients with heart failure / Y. Gunes, M. Tuncer, U. Guntekin, S. Akdag, H. Gumrukcuoglu [et al.] // Pacing Clin Electrophysiol. – 2008. – C. 974-978.
195. Kautzner J. QT interval dispersion and its clinical utility / J. Kautzner, M. Malik // Pacing Clin Electrophysiol. – 1997. – № 20. – C. 2625-2640.
196. Basil M. ECG Abnormalities Associated With Hypocalcemia / M. Basil, . RuDusky // Chest journal. – 2001. – № 8. – C. 239-242.
197. Christopher B. Hypocalcemia / B. Christopher // Emergency Medicine. – 2009. – № 5. – C. 531-535.
198. The QT Interval and Serum Ionized Calcium / W. Rumancik, J. Denlinger, L. Michael, B. Robert [et al.] // JAMA. – 1978. – C. 366-368.
199. Cubeddu L. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs / L. Cubeddu // Am J Ther. – 2003. – № 10. – C. 452-457.
200. Roden D. Drug-induced prolongation of the QT interval / D. Roden // N Engl J Med. – 2004. – № 3511. – C. 1013-1022.
201. Bisinov E. FACC Potassium andlong QT syndrome / E. Bisinov, H. James, T. Craig // J Am Coll Cardiol. – 2003. – № 42. – C. 1783-1784.
202. Prolongation of the QT interval in primary aldosteronism / K. Matsumura, K. Fujii, Y. Kansui, H. Arima, M. Iida [et al.] // Clinical and Experimental Pharmacology and Physiology. – 2008. – C. 66-69.
203. Vorchheimer D. What is QT interval prolongation? / D. Vorchheimer // Journal of Family Practice. – 2005. – № 6. – C. 84-89.
204. Аритмии сердца : в 3 т. / [ред. Мандела В. Дж.]. – Москва : “Медицина”, 1996.
205. Haigney M. Tissue magnesium levels and the arrhythmic substrate in humans / M. Haigney, R. Berger, S. Schulman // J Cardiovasc Electrophysiol. – 1997. – № 8. – C. 980-986.
206. The QT interval / M. Bednar, E. Harrigan, R. Anziano, A. Camm, J. Ruskin [et al.] // Prog Cardiovasc Dis. – 2001. – C. 1-45.
207. Surawicz B. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarization? / B. Surawicz // J Am Coll Cardiol. – 1989. – № 14. – C. 172-184.
208. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans / W. Schmeling, D. Warltier, D. McDonald, K. Madsen, J. Atlee, J. Kampine [et al.] // Anesth Analg. – 1991. – C. 137-144.
209. The effects of volatile anesthetics on the QTc interval / N. Guler, I. Kati, C. Demirel, M. Bilge, B. Eryonucu, C. Topal [et al.] // J Cardiothorac Vasc Anesth. – 2001. – C. 188-191.
210. Anaesthesia and the QT interval in humans: effects of halothane and isoflurane in premedicated children / D. Michaloudis, O. Fraidakis, T. Lefaki, F. Kanakoudis, H. Askitopoulou [et al.] // Eur J Anaesthesiol. – 1998. – C. 623-628.
211. Doig J. Drug-induced cardiac arrhythmias: incidence, prevention, and management / J. Doig // Drug Saf. – 1997. – № 17. – C. 265-275.
212. Thomas S. Drugs, QT interval abnormalities and ventricular arrhythmias / S. Thomas // Adverse Drug React Toxciol Rev. – 1994. – № 13. – C. 77-7102.
213. Viskin S. Long QT syndromes and torsades de pointes / S. Viskin // Lancet. – 1999. – № 354. – C. 1625-1633.
214. Cardiac T. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction / T. Cardiac // N Engl J Med. – 1989. – № 321. – C. 406-412.
215. Maghurabi R. Tambocor (flecainide) use experience / R. Maghurabi // Drugs. – 1987. – № 17. – C. 22-24.
216. The proarrhythmic effects of flecainide / A. Nathan, K. Hellestrand, R. Bexton, R. Spurrell, A. Camm [et al.] // Drugs. – 1985. – C. 45-53.
217. Compared effects of sotalol, flecainide and propafenone on ventricular repolarization in patients free of underlying structural heart disease / B. Sarubbi, V. Ducceschi, N. Briglia, M. Mayer, L. Santangelo, A. Iacono [et al.] // Int J Cardiol. – 1998. – C. 157-164.
218. Day C. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals / C. Day, J. McComb, R. Campbell // Br Heart J. – 1990. – № 63. – C. 342-344.
219. Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle / D. Katritsis, E. Rowland, S. O'Nunain, C. Shakespeare, J. Poloniecki, A. Camm [et al.] // Eur Heart J. – 1995. – C. 1930-1935.
220. Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly? / R. Rocha, G. Silva, E. Perin, A. Gerk, E. Gouvea, V. Santos, F. Filho, d. Albuquerque [et al.] // Eur Heart J. – 1997. – C. 460-463.
221. Effect of nebivolol on QT dispersion in hypertensive patients with left ventricular hypertrophy / F. Galetta, F. Franzoni, A. Magagna, F. Femia, F. Pentimone, G. Santoro, A. Carpi [et al.] // Biomed Pharmacother. – 2005. – C. 15-19.
222. Effects of metoprolol on QT interval and QT dispersion in Type 1 diabetic patients with abnormal albuminuria / E. Ebbehoj, H. Arildsen, K. Hansen, C. Mogensen, H. Molgaard, P. Poulsen [et al.] // Diabetologia. – 2004. – C. 1009-1015.
223. Effect of atenolol on QTc interval lengthening during hypoglycaemia in type 1 diabetes / S. Lee, N. Harris, R. Robinson, C. Davies, R. Ireland, I. Macdonald, S. Heller [et al.] // Diabetologia. – 2005. – C. 1269-1272.
224. Effect of atenolol on QT interval and dispersion in patients with syndrome X / F. Leonardo, G. Fragasso, G. Rosano, P. Pagnotta, S. Chierchia [et al.] // Am J Cardiol. – 1997. – C. 789-790.
225. Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil / Y. Yoshiga, A. Shimizu, T. Yamagata, T. Hayano, T. Ueyama, M. Ohmura, K. Itagaki, M. Kimura, M. Matsuzaki [et al.] // Circ J. – 2002. – C. 1024-1028.
226. Farhangi V. QTc prolongation due to propranolol overdose / V. Farhangi, R. Sansone // Int J Psychiatry Med. – 2003. – № 33. – C. 201-202.
227. Hohnloser S. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management / S. Hohnloser // Am J Cardiol. – 1997. – № 80. – C. 82-89.
228. Soyka L. Clinical safety profile of sotalol in patients with arrhythmia / L. Soyka, C. Wirtz, R. Spengenburg // Am J Cardiol. – 1990. – № 65. – C. 74-81.
229. Hohnloser S. Incidence, type, and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF / S. Hohnloser, W. Arendts, B. Quart // Pacing Clin Electrophysiol. – 1992. – № 15. – C. 173-173.
230. Sex differences in risk of torsades de pointes with d,l sotalol / M. Lehmann, S. Hardy, D. Archibald, B. Quart, D. MacNeil [et al.] // Circulation. – 1996. – C. 2534-2541.
231. Hohnloser S. Amiodarone-associated proarrhythmic effects: a review with special reference to torsades de pointes tachycardia / S. Hohnloser, T. Klingenheben, B. Singh // Ann Intern Med. – 1994. – № 121. – C. 529-535.
232. Jafari-Fesharaki M. Adverse effects of amiodarone / M. Jafari-Fesharaki, M. Scheinman // Pacing Clin Electrophysiol. – 1998. – № 21. – C. 108-120.
233. Howard P. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter / P. Howard // Ann Pharmacother. – 1999. – № 33. – C. 38-47.
234. Pedersen H. DIAMOND Study Group. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide / H. Pedersen, H. Elming, M. Seibaek // Am J Cardiol. – 2007. – № 100. – C. 876-880.
235. Crouch . Drug-Related QT Interval Prolongation: Drugs Associated with QT Prolongation / . Crouch, . Limon, . Cassano // Pharmacotherapy. – 2003. – № 23. – C. 17-20.
236. HERG and KvLQT1/IsK, the cardiac K[+] channels involved in long QT syndromes, are targets for calcium channel blockers / C. Chouabe, M. Driel, G. Romey, J. Barhanin, M. Lazdunski [et al.] // Mol Pharmacol. – 1998. – C. 695-703.
237. Electrocardiographic effects of probucol: a controlled prospective clinical trial / C. Dujovne, F. Atkins, B. Wong, S. DeCoursey, P. Krehbiel, S. Chernoff [et al.] // Eur J Clin Pharmacol. – 1984. – C. 735-739.
238. Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug / K. Browne, E. Prystowsky, J. Heger, B. Cerimele, N. Fineberg, D. Zipes [et al.] // Am Heart J. – 1984. – C. 680-684.
239. Crome P. Antidepressant overdosage / P. Crome // Drugs. – 1982. – № 23. – C. 431-461.
240. Thorstrand C. Clinical features in poisonings by tricyclic antidepressants with special reference to the ECG / C. Thorstrand // Acta Medica Scandinavica. – 1976. – № 199. – C. 337-344.
241. Herrmann H. QT prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline / H. Herrmann, L. Kaplan, B. Bierer // Am J Cardiol. – 1983. – № 81. – C. 904-906.
242. Leonard H. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents / H. Leonard, M. Meyer, S. Swedo // J Am Acad Child Adolesc Psychiatry. – 1995. – № 34. – C. 1460-1468.
243. Biederman J. A naturalistic study of 24-hour electrocardiographic findings in children and adolescents treated with desipramine / J. Biederman, R. Baldessarini, A. Goldblatt // J Am Acad Child Adolesc Psychiatry. – 1993. – № 32. – C. 805-813.
244. Riddle M. Another sudden death in a child with desipramine / M. Riddle, B. Geller, N. Ryan // J Am Acad Child Adolesc Psychiatry. – 1993. – № 32. – C. 792-797.
245. Baker B. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder / B. Baker, P. Dorian, P. Sandon // J Clin Psychopharmacol. – 1997. – № 17. – C. 15-21.
246. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline / A. Teschemacher, E. Seward, J. Hancox, H. Witchel [et al.] // Br J Pharmacol. – 1999. – C. 479-485.
247. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects: is there any? / P. Pacher, Z. Ungvari, P. Nanasi, S. Furst, V. Keeskemeti [et al.] // Curr Med Chem. – 1999. – C. 469-480.
248. ECG changes after paroxetine: 3 case reports / A. Erfurth, M. Loew, P. Dobmeier, G. Wendler [et al.] // Nervenarzt. – 1998. – C. 629-631.
249. Sudden cardiac death with clozapine and sertraline combination / J. Hoehns, M. Fouts, M. Kelly, T. KB [et al.] // Ann Pharmacother. – 2001. – C. 862-866.
250. Beelen A. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone / A. Beelen, K. Yeo, L. Lewis // Hum Exp Toxicol. – 2001. – № 20. – C. 215-219.
251. Torsades de pointes occurring in association with terfenadine use / B. Monahan, C. Ferguson, E. Killeavy, B. Lloyd, J. Troy, L. Cantilena [et al.] // JAMA. – 1990. – C. 2788-2790.
252. Zimmermann M. Torsades de pointes after treatment with terfenadine and ketoconazole / M. Zimmermann, H. Duruz, O. Guinand // Eur Heart J. – 1992. – № 13. – C. 1002-1003.
253. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin / P. Honig, R. Woosley, K. Zamani, D. Conner, L. Cantilena [et al.] // Clin Pharmacol Ther. – 1992. – C. 231-238.
254. Clark A. Astemizole-induced ventricular arrhythmias: an unexpected case of convulsions / A. Clark, H. Love // Int J Cardiol. – 1991. – № 33. – C. 165-167.
255. Cardiotoxic effects of astemizole overdose in children / J. Wiley, M. Gelber, F. Henretig, C. Wiley, S. Sandhu, J. Loiselle [et al.] // J Pediatr. – 1992. – C. 799-802.
256. Berul C. Regulation of potassium channels by nonsedating antihistamines / C. Berul, M. Morad // Circulation. – 1995. – № 91. – C. 2220-2225.
257. Electrocardiographic findings in patients with diphenhydramine overdose / W. Zareba, A. Moss, S. Rosero, R. Hajj-Ali, J. Konecki, M. Andrews [et al.] // Am J Cardiol. – 1997. – C. 1168-1173.
258. Electro-physiological mechanisms in a canine model of erythromycin-associated long QT syndrome / M. Rubart, M. Pressler, H. Pride, D. Zipes [et al.] // Circulation. – 1993. – C. 1832-1844.
259. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature / S. Tschida, D. Guay, R. Straka, L. Hoey, R. Johanning, K. Vance-Bryan [et al.] // Pharmacotherapy. – 1996. – C. 663-674.
260. A review of erythromycin-induced malignant tachyarrhythmia- torsades de pointes: a case report / K. Katapadi, G. Kostandy, M. Katapadi, K. Hussain, D. Schifter [et al.] // Angiology. – 1997. – C. 821-826.
261. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism / S. Nattel, S. Ranger, M. Talajic, R. Lemery, D. Roy [et al.] // Am J Med. – 1990. – C. 235-238.
262. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de points / B. Darpo // Eur Heart J. – 2001. – № 3. – C. 70-80.
263. McComb J. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin / J. McComb, N. Campbell, J. Cleland // Am J Cardiol. – 1984. – № 54. – C. 922-923.
264. Rezkalla M. Erythromycin induced torsades de pointes: case report and review of the literature / M. Rezkalla, C. Pochop // S D J Med. – 1994. – № 47. – C. 161-164.
265. QT prolongation and recurrent 'torsades de pointes' during erythromycin administration / D. Guelon, B. Bedock, C. Chartier, J. Haberer [et al.] // Am J Cardiol. – 1986. – C. 666-666.
266. Gitler B. Torsades de pointes induced by erythromycin / B. Gitler, L. Berger, S. Buffa // Chest. – 1994. – № 105. – C. 368-372.
267. Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval / S. Chennareddy, M. Siddique, M. Karim, V. Kudesia [et al.] // Am Heart J. – 1996. – C. 691-694.
268. Cardiac actions of erythromycin: influence of female sex / M. Drici, B. Knollman, W. Wang, R. Woosley [et al.] // JAMA. – 1998. – C. 1774-1778.
269. QT prolongation and torsades de pointes associated with clarithromycin / K. Lee, M. Jim, S. Tang, Y. Tai [et al.] // Am J Med. – 1998. – C. 395-396.
270. QT prolonging drugs: mechanisms and clinical relevance of the arrhythmogenic hazards / M. Zehender, . Hohnloser, . S, H. Just [et al.] // Cardiovasc Drugs Ther. – 1991. – C. 515-530.
271. Shaffer D. Macrolide antibiotics and torsades de pointes postmarketing analysis / D. Shaffer, S. Singer // Telithromycin Advisory Committee. – 2001. – № 1. – C. 15-17.
272. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG / J. Kang, L. Wang, X. Chen, D. Triggle, D. Rampe [et al.] // Mol Pharmacol. – 2001. – C. 122-126.
273. Balfour J. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections / J. Balfour, H. Lamb // Drugs. – 2000. – № 59. – C. 115-139.
274. Sacks L. A review of the safety of moxifloxacin hydrochloride / L. Sacks // Drugs. – 2000. – № 24. – C. 59-63.
275. Dumaine R. Blockade of HERG and Kv1.5 by ketoconazole / R. Dumaine, M. Roy, A. Brown // J Pharmacol Exp Ther. – 1998. – № 286. – C. 727-735.
276. Paserchia L. Effects of ketoconazole on QTc [abstr] / L. Paserchia, J. Hewett, R. Woosley // Clin Pharmacol Ther. – 1994. – № 55. – C. 146-146.
277. Fluconazole-induced torsades-de pointes / V. Tholakanahalli, A. Potti, J. Hanley, A. Merliss [et al.] // Ann Pharmacother. – 2001. – C. 432-434.
278. Wassman S. Long QT syndrome and torsades de pointes in a patient receiving fluconazole / S. Wassman, G. Nickenig, M. Bohm // Ann Intern Med. – 1999. – № 131. – C. 797-797.
279. Tie H. Inhibition of HERG potassium channels by the antimalarial agent halofantrine / H. Tie, B. Walker, C. Singleton // Br J Pharmacol. – 2000. – № 140. – C. 1967-1975.
280. Monlun E. Cardiac complications of halofantrine: a prospective study of 20 patients / E. Monlun, L. Metayer, S. Szwandt // Trans R Soc Trop Med Hyg. – 1995. – № 89. – C. 430-433.
281. White N. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria / N. White, S. Looareesuwan, D. Warrell // J Cardiovasc Pharmacol. – 1983. – № 5. – C. 173-175.
282. Martin E. Quinine may trigger torsades de pointes during astemizole therapy / E. Martin, K. Rogalski, J. Black // Pacing Clin Electrophysiol. – 1997. – № 20. – C. 2024-2025.
283. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients / P. Laothavorn, J. Karbwang, N. Bangchang, D. Bunnag, T. Harinasuta [et al.] // Southeast Asian J Trop Med Public Health. – 1992. – C. 51-54.
284. Nosten F. Cardiac effects of antimalarial treatment with halofantrine / F. Nosten, F. Kuile, C. Luxemburger // Lancet. – 1993. – № 341. – C. 1054-1056.
Як цитувати
Kulyk, V., & Iabluchanskyi, M. (1). QT INTERVAL IN CARDIOLOGIC CLINICS. Вісник Харківського національного університету імені В. Н. Каразіна. Серія «Медицина», (18), 73-96. вилучено із https://periodicals.karazin.ua/medicine/article/view/6959
Номер
Розділ
Reviews
Вісник Харківського національного університету імені В. Н. Каразіна, серія Медицина має такі умови авторського права:
1. Автори зберігають авторські права та надають журналу право на першу публікацію разом із роботою, яка одночасно ліцензується згідно з ліцензією Creative Commons Attribution License, яка дозволяє іншим ділитися роботою з визнанням авторства роботи та першої публікації в цьому журналі.
2. Автори можуть укладати окремі додаткові договірні угоди щодо неексклюзивного розповсюдження опублікованої журналом версії роботи з підтвердженням її початкової публікації в цьому журналі.
3. Авторам дозволяється та заохочується публікувати свої роботи в Інтернеті до та під час процесу подання, оскільки це може призвести до продуктивного обміну, а також до раннього та більшого цитування опублікованої роботи.
